JP5916327B2 - Absorbent articles - Google Patents

Description

  The present invention relates to an absorbent article that absorbs menstrual blood, such as a sanitary napkin and a cage absorption liner.

  Disposable absorbent articles having a liquid permeable topsheet with a lotion in the form of a pattern consisting of a plurality of strips separated by a plurality of non-lotion areas are known in the art (eg, patents) Reference 1). By applying a lotion to the top sheet in the shape of the above pattern, the absorbent article described in Patent Document 1 has a very comfortable wearing feeling and can be provided with an excellent absorbency.

Japanese translation of PCT publication No. 2008-522772

  However, in the absorbent article described in Patent Document 1, the effect of the lotion is not obtained in the region where the lotion between the strips to which the lotion is applied is not applied. In addition, due to the effect of lotion, the adhesive strength of the hot melt adhesive (HMA) that adheres the top sheet to the back sheet is weakened, and the strength of the absorbent article may be reduced.

  The present invention suppresses the decrease in strength of the absorbent article due to the application of the blood modifying agent to the top sheet, makes it difficult for high viscosity menstrual blood to remain on the top sheet, eliminates the stickiness of the top sheet, and absorbs It aims at providing the absorbent article which exhibits the effect of the blood modifier which can make an article | item have a smooth feeling.

The present invention employs the following configuration in order to solve the above problems.
The present invention has a longitudinal direction and a width direction, a liquid-permeable top sheet provided on the skin side, a liquid-impermeable back sheet provided on the clothing side, and between the top sheet and the back sheet. An absorbent article comprising an intervening liquid-retaining absorbent body and a pair of side sheets provided on both sides in the width direction of the top sheet, wherein the top sheet has a blood modification coated with a blood modifying agent. The blood modifying agent has an IOB of 0 to 0.60, a melting point of 45 ° C. or less, and a water solubility of 0.05 g or less with respect to 100 g of water at 25 ° C., and blood The modifier application area does not reach the end of the absorbent article.

  According to the present invention, while suppressing a decrease in strength of the absorbent article due to the application of the blood modifying agent to the top sheet, high viscosity menstrual blood hardly remains on the top sheet, eliminating the sticky feeling of the top sheet, The absorbent article can have a smooth feeling.

FIG. 1 is a partially broken plan view of an absorbent article according to a first embodiment of the present invention. FIG. 2 is a schematic cross-sectional view showing a cross section taken along line AA of FIG. FIG. 3 is a plan view of an absorbent article according to the second embodiment of the present invention. FIG. 4 is a plan view of an absorbent article according to a third embodiment of the present invention. FIG. 5 is a schematic cross-sectional view showing a cross section taken along the line CC of FIG. FIG. 6 is a plan view of an absorbent article according to a fourth embodiment of the present invention. FIG. 7 is a plan view of an absorbent article according to a fifth embodiment of the present invention. FIG. 8 is a plan view of an absorbent article according to a sixth embodiment of the present invention. FIG. 9 is a diagram showing a range in which the top sheet contains a blood modifying agent in Example 1. FIG. 10 is an electron micrograph of the skin contact surface of the top sheet in a sanitary napkin in which the top sheet contains tri-C2L oil fatty acid glycerides. FIG. 11 is a photomicrograph of menstrual blood with or without a blood modifying agent. FIG. 12 is a diagram for explaining a method of measuring surface tension.

(First embodiment)
Hereinafter, an absorbent article according to a first embodiment of the present invention will be described with reference to the drawings. However, the present invention is not limited to what is described in the drawings.

  FIG. 1 is a partially broken plan view of an absorbent article according to a first embodiment of the present invention, and FIG. 2 is a schematic cross-sectional view showing a cross section taken along line AA of FIG. The absorbent article 1A is interposed between a liquid-permeable top sheet 2 provided on the skin side, a liquid-impermeable back sheet 3 provided on the clothing side, and between the top sheet 2 and the back sheet 3. A liquid retaining absorbent body 4 and a pair of side sheets 5 provided on both sides in the width direction of the top sheet 2 are included. The absorbent article 1 </ b> A includes a main body 6 and a pair of wings 7 extending from the main body 6 in the width direction. The top sheet 2 has a blood modifying agent application region 8A to which a blood modifying agent is applied. The top sheet 2 and the back sheet 3 are joined by a seal portion 9 by embossing. Further, the back sheet 3 and the side sheet 5 are joined by the seal portion 10 by embossing. The seal portions 9 and 10 are provided on the outer periphery of the absorbent article 1. Adhesive portions 11 and 12 are provided on the clothing side surface of the backsheet 3. In FIG. 1, the width direction of the absorbent article 1A is the X-axis direction, and the longitudinal direction is the Y-axis direction. The plane direction is a direction of a plane extending in the X-axis and Y-axis directions.

  The shape of the main body 6 is not particularly limited as long as it is a shape that matches the shape of the female body and the shorts, such as a substantially rectangular shape, a substantially oval shape, and a substantially saddle shape. The total length in the longitudinal direction of the outer shape of the main body 6 is preferably 100 to 500 mm, and more preferably 150 to 350 mm. Moreover, the total dimension of the width direction in the external shape of the main-body part 6 becomes like this. Preferably it is 30-200 mm, More preferably, it is 40-180 mm.

  The top sheet 2 allows menstrual blood discharged from the wearer to pass through the absorber 4 provided therebelow. Further, the top sheet 2 holds the absorber 4 by sandwiching the absorber 4 with the back sheet 3. The top sheet 2 is wholly or partially liquid permeable, and the liquid permeable area of the top sheet 2 is a liquid permeable nonwoven fabric, a woven fabric, a resin film in which a large number of liquid permeable holes are formed, or a large number of meshes. It can be formed of a net-like sheet or the like.

  As the raw material of the nonwoven fabric or woven fabric used for the top sheet 2, either natural fibers or chemical fibers can be used. Examples of natural fibers include cellulose such as pulverized pulp and cotton. Examples of the chemical fiber include regenerated cellulose such as rayon and fibril rayon, semi-synthetic cellulose such as acetate and triacetate, thermoplastic hydrophobic chemical fiber, and thermoplastic hydrophobic chemical fiber subjected to hydrophilic treatment. Examples of thermoplastic hydrophobic chemical fibers include single fibers such as polyethylene (PE), polypropylene (PP), and polyethylene terephthalate (PET), fibers formed by graft polymerization of PE and PP, and composite fibers such as a core-sheath structure. It is done.

  When producing a nonwoven fabric to be used for the top sheet 2, web forming is carried out by any of dry methods (card method, spunbond method, melt blown method, airlaid method, etc.) and wet methods, or a combination of dry methods and wet methods. Also good. Examples of the method for bonding the web when producing the nonwoven fabric used for the top sheet 2 include thermal bonding, needle punching, and chemical bonding, but are not limited to these methods. A spunlace formed into a sheet shape by the hydroentanglement method may be used for the top sheet 2. In addition, the nonwoven fabric with irregularities formed on the upper layer side by shrinking the lower layer side using heat-shrinkable fibers and the like, and the skin side surface such as the nonwoven fabric with irregularities formed by applying air when forming the web were provided with irregularities. A nonwoven fabric may be used as the top sheet 2. Thus, the contact area between the top sheet 2 and the skin can be reduced by making the skin side surface uneven.

  As the non-woven fabric fiber used for the top sheet 2, a core-sheath type in which the melting point of the core component is higher than that of the sheath component, an eccentric type of the core-sheath, or a side-by-side type composite fiber having different melting points of the left and right components may be used. In addition, hollow fibers, flat fibers, Y-shaped and C-shaped fibers, three-dimensional crimped fibers of latent crimp or actual crimp, and splitting by physical load such as water flow, heat or embossing Fibers such as fibers may be mixed in the nonwoven fabric used for the top sheet 2.

  Considering the penetration of the liquid and the touch, the fineness of the non-woven fabric used for the top sheet 2 is preferably 1.1 to 8.8 dtex.

  When using a hydrophobic synthetic fiber for the top sheet 2, considering the liquid penetration and rewet back of the top sheet 2, a hydrophilic agent or a water repellent is kneaded into the hydrophobic synthetic fiber, The hydrophobic synthetic fiber may be coated with a liquid agent or the like. Further, hydrophilicity may be imparted to the hydrophobic synthetic fiber by corona treatment or plasma treatment. As a result, when the blood modifying agent is lipophilic, hydrophilic portions and lipophilic portions coexist sparsely in the blood modifying agent application region 8A, and the hydrophilic components of menstrual blood (mainly blood Both soy and lipophilic components (mainly blood cells) migrate from the top sheet 2 to the absorbent body 4 quickly.

  In order to improve the concealability of the top sheet 2, the nonwoven fabric fibers used in the top sheet 2 may contain an inorganic filler such as titanium oxide, barium sulfate, and calcium carbonate. When the nonwoven fabric fiber is a core-sheath type composite fiber, an inorganic filler may be contained only in the core, or only in the sheath.

  When a resin film or a net-like sheet is used as the top sheet 2, the resin film or the net-like sheet can be formed from polypropylene (PP), polyethylene (PE), polyethylene terephthalate (PET), or the like.

  As described above, the top sheet 2 has the blood modifying agent application region 8A to which the blood modifying agent is applied. Details of the blood modifying agent will be described later. As shown in FIG. 1, blood modifying agent application region 8A does not reach the end of absorbent article 1A. Thereby, it can suppress that the junction of the edge part of an absorbent article becomes weak with a blood modifier, and can suppress that the intensity | strength of 1 A of absorbent articles becomes weak. Moreover, the application amount of the blood modifying agent can be reduced, and the manufacturing cost of the absorbent article 1A can be reduced.

  The blood modifying agent application region 8A is preferably in the range of the absorber existing region (4). Here, the absorber existence area (4) is an area where the absorber 4 is present on the clothing side of the topsheet 2 in the topsheet 2. As will be described later, the blood modifying agent lowers the viscosity and surface tension of menstrual blood and can quickly transfer menstrual blood from the top sheet 2 to the absorbent body 4, so that menstrual blood discharged by the wearer is It becomes difficult to spread from the blood modifying agent application region 8A to the outer plane direction. Therefore, menstrual blood discharged to the top sheet 2 by the wearer can be prevented from spreading outside the absorber existence region (4). Moreover, the application amount of the blood modifying agent can be further reduced, and the manufacturing cost of the absorbent article 1A can be reduced.

  It is more preferable that the blood modifying agent application region 8A does not reach the seal portions 9 and 10 existing on the outer periphery of the absorbent article 1A. Thereby, it can suppress that joining of the seal parts 9 and 10 becomes weak with a blood modifier, and can suppress that the intensity | strength of 1 A of absorbent articles becomes weak, or 1 A of absorbent articles decompose | disassemble. Moreover, the application amount of the blood modifying agent can be reduced, and the manufacturing cost of the absorbent article 1A can be reduced.

  More preferably, blood modifying agent application region 8A does not reach region 12 (see FIG. 2) where top sheet 2 and side sheet 5 overlap. Thereby, it can suppress that the joining between the top sheet 2 and the side sheet | seat 5 becomes weak with a blood modifier, and the intensity | strength of 1 A of absorbent articles becomes weak, or 1 A of absorbent articles decompose | disassemble. Can be suppressed.

  The length in the length direction of the blood modifying agent application region 8A is preferably 50 mm or more, and more preferably 100 mm or more. The length in the width direction of the blood modifying agent application region 8A is preferably 10 mm or more, and more preferably 30 mm or more.

Coating basis weight of the blood modifying agent to the top sheet 2 is preferably 1 to 30 g / m ^2, more preferably 3 to 10 g / m ^2. If the coating weight of the blood modifying agent is less than 1 g / m ² , it may be difficult to stably apply the blood modifying agent to the top sheet 2, and the coating weight of the blood modifying agent is 30 g / m ^2. If it is larger than m ² , the top sheet 2 may become slimy.

  The blood modifying agent is heated to a desired temperature and then applied to the top sheet 2 using a contact coater such as a slot coater, or a non-contact coater such as a spray coater, curtain coater, or spiral coater. Since the blood modifying agent in the form of droplets can be uniformly dispersed in the blood modifying agent application region 8A and the top sheet 2 is not damaged, the blood modifying agent is applied to the top sheet using a non-contact coater. 2 is preferably applied.

  When producing the nonwoven fabric for top sheets, a blood modifying agent may be applied to the nonwoven fabric. Further, the blood modifying agent may be applied to the top sheet 2 in the manufacturing process of the absorbent article 1A. However, since the capital investment can be suppressed, it is preferable to apply the blood modifying agent to the top sheet 2 in the manufacturing process of the absorbent article 1A. In addition, in order to prevent the blood modifying agent applied to the top sheet 2 from decreasing during the manufacturing process of the absorbent article 1A, the blood modifying agent is applied to the top sheet in a process close to completion of the absorbent article 1A. 2 is preferably applied. For example, the blood modifying agent may be applied to the top sheet 2 immediately before the step of packaging the absorbent article 1A.

The backsheet 3 prevents menstrual blood absorbed by the absorber 4 from leaking out. The back sheet has a liquid-impermeable film mainly composed of polyethylene (PE) and polypropylene (PP), a breathable resin film, and a composite in which a breathable resin film is bonded to a nonwoven fabric such as spunbond or spunlace. For example, an SMS nonwoven fabric in which a melt-blown nonwoven fabric having high water resistance is sandwiched between strong spunbond nonwoven fabrics can be used. In order to make the absorbent article 1A flexible so as not to impair the wearing feeling of the absorbent article 1A, the backsheet 3 has, for example, a basis weight of 15 to 30 g / m ² mainly composed of low density polyethylene (LDPE) resin. It is preferable to use a resin film.

  The absorber 4 has a function of absorbing and holding menstrual blood. It is preferable that the absorber 4 is bulky, does not easily lose its shape, and has little chemical stimulation. As the absorbent body 4, for example, an absorbent body in which a hydrophilic fiber or an absorbent polymer (SAP) is covered with a coating material and an absorbent body made of fluffy pulp or airlaid nonwoven fabric and a superabsorbent polymer can be used.

  The hydrophilic fibers of the absorbent body 4 in which hydrophilic fibers and absorbent polymers are covered with a covering material include cellulose such as pulverized pulp and cotton, regenerated cellulose such as rayon and fibril rayon, semi-synthetic cellulose such as acetate and triacetate, particles Polymer, fibrous polymer, thermoplastic hydrophobic chemical fiber, thermoplastic hydrophobic chemical fiber subjected to hydrophilic treatment, and mixtures thereof. Cellulose foams and continuous foams of synthetic resins can also be used for the absorbent body 4. Furthermore, it is also possible to use for the absorber 4 what was formed into the shape of the absorber after pulverizing the foamed material or sheet material. Among these, it is preferable to use pulverized pulp as the hydrophilic fiber of the absorbent body 4 in view of low cost and easy molding.

  As the superabsorbent polymer of the absorbent body 4, a granular polymer such as a sodium acrylate copolymer having absorbency and hygroscopicity is generally used. In order to impart other functions to the polymer, silver, copper, zinc, silica, activated carbon, an aluminosilicate compound, zeolite, or the like may be added to the polymer. Thereby, functions, such as a deodorizing property, antibacterial property, or an endothermic effect, can be provided to a polymer.

  The covering material of the absorbent body 4 in which the hydrophilic fiber or the absorbent polymer is covered with the covering material is not particularly limited as long as it has liquid permeability and a barrier property that the polymer absorbent body does not slip through. For example, a woven fabric or a non-woven fabric can be used for the covering material. As the material for the woven fabric and the nonwoven fabric, either natural fibers or chemical fibers can be used. Natural fibers include cellulose such as ground pulp and cotton. The chemical fiber includes regenerated cellulose such as rayon and fibril rayon, semi-synthetic cellulose such as acetate and triacetate, thermoplastic hydrophobic chemical fiber, and thermoplastic hydrophobic chemical fiber subjected to a hydrophilic treatment.

  In the manufacturing method of the nonwoven fabric used for the coating material, the web forming is performed by either a dry method (a card method, a spunbond method, a melt blown method, an airlaid method, etc.) or a wet method, or a combination of a dry method and a wet method. . Examples of the bonding method of the nonwoven fabric used for the covering material include thermal bonding, needle punching, chemical bonding, and the like, but are not particularly limited to these methods. Moreover, you may use the spunlace formed in the sheet form by the hydroentanglement method for a coating material. Among these, considering the low cost and the high barrier property, the coating material is preferably a tissue that is formed by a wet method using pulverized pulp as a main material.

  The absorber may be embossed in order to adjust the shape and distortion of the absorbent body 4 being worn, and to adjust the thickness. The embossing of the absorbent body 4 is performed, for example, by passing the absorbent body between a patterned emboss roll and a flat roll. The pattern of the embossing roll is selected from a lattice shape, a dot shape, a wave shape, and the like, but a lattice pattern that allows easy adjustment of the thickness is preferable. By embossing the absorbent body 4, diffusion of menstrual blood can be induced in the longitudinal direction of the absorbent article 1A. Moreover, the menstrual blood diffused in the absorbent body 4 can be hardly seen from the surface of the absorbent article 1A.

  Absorbent sheets and polymer sheets can be used for the absorbent body 4. Thereby, the absorber 4 can be made thin. In this case, the thickness of the absorber 4 is preferably 0.3 to 5 mm. Examples of the absorbent sheet include a pulp sheet obtained by forming a fiber into a sheet using a binder or the like. Examples of the polymer sheet include a pulverized pulp mixed with a particulate polymer or a composite sheet in which fibers are formed into a sheet shape. In addition, in the sheet formed by mixing the particulate polymer with the fiber into a sheet shape, the particulate polymer is dispersed in layers in the fiber, and the particulate polymer is dispersed in three dimensions in the fiber. The sheet etc. which are done are mentioned. Fibers used for absorbent sheets or polymer sheets include cellulose fibers such as wood pulp, regenerated cellulose fibers such as rayon and cupra, hydrophilic synthetic fibers such as polyvinyl alcohol fibers and polyacrylonitrile fibers, and fibers such as surfactants. Fibers such as polyethylene, polypropylene, polyethylene terephthalate, polyethylene / polypropylene composite fiber, polyethylene / polyethylene terephthalate composite fiber having a hydrophilic surface are preferably used. Cellulose fibers are more preferable for the fibers used in the absorbent sheet or polymer sheet from the viewpoint of maintaining good hydrophilicity of the fibers. The particulate polymer used for the polymer sheet is preferably a polymer that can absorb and retain a liquid having a weight 20 times or more of its own weight and can gel. Such polymers include starch, cross-linked carboxymethylated cellulose, polyacrylic acid and its salts, and polyacrylate graft polymers.

  The side sheet 5 prevents menstrual blood from leaking through the top sheet 2 to the outside in the width direction of the absorbent article 1. The side sheet 5 preferably has hydrophobicity or water repellency. For the side sheet 5, for example, a spunbond nonwoven fabric or an SMS nonwoven fabric is used. Moreover, since the side sheet | seat 5 contacts a wearer's skin, it is preferable to use the air through nonwoven fabric for the side sheet | seat 5 which can reduce the rub irritation | stimulation to skin. The side sheet is not essential for the absorbent article, and the side sheet may not be provided on the absorbent article.

  It is preferable that the top sheet 2, the back sheet 3, the absorbent body 4, and the side sheet 5 are joined to each other in order to prevent interlayer separation. For these joints, for example, an embossing, an ultrasonic wave, an adhesive such as a hot melt adhesive, and a combination thereof can be used. The top sheet 2 and the back sheet 3 are joined at the seal portion 9 by embossing. The back sheet 3 and the side sheet 5 are joined at the seal portion 10 by embossing. The top sheet 2 and the side sheet 5 are bonded to each other on the both sides of the main body 6 by a hot melt adhesive. The top sheet 2 and the back sheet 3 may be joined at the seal portion 9 with an adhesive.

  As an example of embossing, the top sheet and back sheet or the top sheet, back sheet and side sheet are passed together between the patterned embossing roll and flat roll, and the periphery of the absorber is embossed. Can be formed (a method called a so-called round seal). Thereby, the seal parts 9 and 10 are formed in the absorbent article 1A. Since each sheet is softened by heating the embossing roll and / or the flat roll, the seal portions 9 and 10 are likely to become clear. Examples of the emboss pattern include a lattice pattern, a staggered pattern, and a wave pattern. In order to make it difficult for the absorbent article 1A to bend at the boundary between the seal portions 9 and 10, it is preferable that the emboss pattern is intermittently elongated.

  When using hot melt adhesives to join top sheets, back sheets, absorbers, and side sheets, hot coating methods such as spiral coating, coater coating, curtain coater coating, and summit gun coating are used. A melt adhesive is applied to each sheet. Then, the sheets are overlapped and the sheets are joined. After the sheets are joined, embossing may be further performed to increase the peel strength between the sheets.

  Hot melt adhesives used for joining sheets are mainly made of rubber such as styrene-ethylene-butadiene-styrene (SEBS), styrene-butadiene-styrene (SBS), and styrene-isoprene-styrene (SIS). Or pressure-sensitive adhesives or heat-sensitive adhesives mainly composed of olefins such as linear low-density polyethylene, or water-soluble polymers such as polyvinyl alcohol, carboxymethyl cellulose and gelatin, or water swellability Examples thereof include water-sensitive adhesives such as high molecular weight polyvinyl acetate and sodium polyacrylate. When the adhesive oozes out on the outer surface, a heat-sensitive adhesive that does not have tackiness is preferably used as a hot-melt adhesive that is used for joining sheets. As a specific example, it is prepared by melt-mixing 5-25% SEBS, 40-60% alicyclic saturated hydrocarbon, 1-10% aromatic modified terpene and 15-35% additive. The adhesive which was made is mentioned.

  The wing part 7 is provided in the absorbent article 1A in order to stably fix the absorbent article 1A to the underwear. The absorbent article 1A can be stably fixed to the undergarment by bending the wing part 7 to the outer surface side of the undergarment and then attaching it to the crotch part of the undergarment via the adhesive part 12. The shape of the wing part 7 is a substantially rectangular shape.

The adhesive part 11 on the clothing side of the backsheet 3 fixes the main body part 6 to the inside of the crotch part of the underwear, and the adhesive part 12 on the clothing side of the wing part 7 fixes the wing part 7 to the outside of the crotch part of the underwear. To do. As the pressure-sensitive adhesive that forms the pressure-sensitive adhesive portions 11 and 12, for example, a styrenic polymer, a tackifier, or a plasticizer is preferably used as a main component. Examples of the styrenic polymer include styrene-ethylene-butylene-styrene block copolymers, styrene-butylene polymers, styrene-butylene-styrene block copolymers, styrene-isobutylene-styrene copolymers, and the like. Only one of them may be used, or two or more of these polymer blends may be used. Among these, a styrene-ethylene-butylene-styrene block copolymer is preferable as the pressure-sensitive adhesive for the pressure-sensitive adhesive portions 10 and 11 in terms of good thermal stability. In addition, organic compounds that are solid at room temperature can be preferably used as the tackifier and the plasticizer. Examples of the tackifier include C5 petroleum resins, C9 petroleum resins, dicyclopentadiene petroleum resins, rosin petroleum resins, polyterpene resins, terpene phenol resins, and plasticizers include, for example, triphosphate phosphate. click Reshiru, dibutyl phthalate, other monomers plasticizers such as dioctyl phthalate, and the like polymeric plasticizers such as vinyl polymer or polyester.

  Next, the blood modifying agent applied to the top sheet 2 will be described in detail. By this blood modifying agent, after the top sheet 2 absorbs menstrual blood with high viscosity, the viscosity and surface tension of menstrual blood are lowered, and menstrual blood can be quickly transferred from the top sheet 2 to the absorber 4. Further, menstrual blood with high viscosity hardly remains on the top sheet 2, and the top sheet 2 has no stickiness and can have a smooth feeling. In addition, this blood modifying agent lowers the viscosity and surface tension of highly viscous menstrual blood, and menstrual blood is transferred to the absorbent body 4, so that a highly viscous menstrual blood mass does not easily remain on the top sheet and is worn. People are less likely to feel visually uncomfortable.

[Blood modifier]
The blood modifying agent according to the present disclosure has an IOB of about 0 to about 0.60, a melting point of about 45 ° C. or less, and a water solubility of about 0.05 g or less at 25 ° C.

IOB (Inorganic Organic Balance) is an index indicating a balance between hydrophilicity and lipophilicity. In the present specification, the following formula by Oda et al.
IOB = value calculated by inorganic value / organic value.

The inorganic value and the organic value are represented by Fujita Minoru, “Prediction of organic compounds and conceptual diagram of organic compounds” in the field of chemistry Vol. 11, no. 10 (1957) p. 719-725).
Table 1 below summarizes the organic and inorganic values of the major groups by Fujita.

For example, in the case of an ester of tetradecanoic acid having 14 carbon atoms and dodecyl alcohol having 12 carbon atoms, the organic value is 520 (CH ₂ , 20 × 26), and the inorganic value is 60 (—COOR, 60 × 1), so that IOB = 0.12.

  In the blood modifying agent, the IOB is about 0 to about 0.60, preferably about 0 to about 0.50, more preferably about 0 to about 0.40, and about 0. More preferred is ~ 0.30. This is because the lower the IOB, the higher the organicity and the higher the affinity with blood cells.

  In the present specification, the “melting point” means a peak top temperature of an endothermic peak when changing from a solid state to a liquid state when measured with a differential scanning calorimeter at a temperature rising rate of 10 ° C./min. The melting point can be measured, for example, using a DSC-60 type DSC measuring apparatus manufactured by Shimadzu Corporation at a temperature rising rate of 10 ° C./min.

  The blood modifying agent may be liquid or solid at room temperature, as long as it has a melting point of about 45 ° C. or lower, that is, whether the melting point is about 25 ° C. or more, or less than about 25 ° C. Well and can have a melting point of, for example, about −5 ° C., about −20 ° C. The reason why the melting point of the blood modifying agent is about 45 ° C. or less will be described later.

  The blood modifying agent has a lower melting point, but preferably has a low vapor pressure. The blood pressure of the blood modifying agent is preferably about 0.01 Pa or less, more preferably about 0.001 Pa or less, and further about 0.0001 Pa or less at 1 atm and 25 ° C. preferable. Considering that the absorbent article of the present disclosure is used in contact with the human body, the vapor pressure is preferably about 0.01 Pa or less at 1 atmosphere and 40 ° C., and is preferably about 0.001 Pa or less. More preferably, it is more preferably about 0.0001 Pa or less. This is because if the vapor pressure is high, vaporization may occur during storage, and problems such as a decrease in the amount of blood modifying agent and odor when worn may occur.

Further, the melting point of the blood modifying agent can be properly used according to the climate, the length of wearing time, and the like. For example, in an area where the average temperature is 10 ° C. or less, even if the menstrual blood is excreted and then cooled by the ambient temperature by adopting a blood modifying agent having a melting point of about 10 ° C. or less, It is considered that the blood modifying agent can stably modify blood.
Further, when the absorbent article is used for a long time, the melting point of the blood modifying agent is preferably higher in the range of 45 ° C. or lower. This is because the blood modifying agent is difficult to move even when it is worn for a long time, and is hardly affected by sweat, friction at the time of wearing, and the like.

The above-mentioned water solubility was determined by adding 0.05 g of sample to 100 g of deionized water at 25 ° C. and allowing it to stand for 24 hours. After 24 hours, lightly stirred as necessary to determine whether the sample was dissolved. Thus, it can be determined whether or not the water solubility is 0.05 g or less.
In the present specification, regarding dissolution in water, “dissolution” includes a case where the sample is completely dissolved in deionized water to form a uniform mixture and a case where the sample is completely emulsified. “Complete” means that there is no lump of sample in deionized water.

  In this technical field, the surface of a top sheet is coated with a surfactant for the purpose of changing the surface tension of blood and the like to absorb blood rapidly. However, since surfactants generally have high water solubility, top sheets coated with surfactants are well-suited to hydrophilic components (blood plasma, etc.) in blood, but rather leave blood on the top sheet. There is a tendency to work. Since the blood modifying agent has low water solubility, it is considered that blood can be quickly transferred to the absorbent body without remaining on the top sheet, unlike conventionally known surfactants.

In the present specification, the solubility in 100 g of water at 25 ° C. may be simply referred to as “water solubility”.
The blood modifying agent can have a water solubility of about 0 g. Therefore, in the blood modifying agent, the lower limit of the water solubility is about 0 g.

Examples of the blood modifying agent include compounds having the following structure.
(I) hydrocarbons,
(Ii) a compound in which at least one carbonyl bond (—CO—) and / or at least one ether bond (—O—) is inserted between C—C single bonds of hydrocarbon, or (iii) At least one carbonyl bond (—CO—) and / or at least one ether bond (—O—) is inserted between the C—C single bonds, and at least one hydrogen atom on the hydrocarbon is a carboxyl group ( -COOH) or a compound substituted with a hydroxyl group (-OH).

  In the present specification, “hydrocarbon” means a compound composed of carbon and hydrogen, and is a chain hydrocarbon, for example, a paraffinic hydrocarbon (also referred to as an alkane, which does not include a double bond and a triple bond). , Olefinic hydrocarbons (including one double bond, also referred to as alkene), acetylenic hydrocarbons (including one triple bond, also referred to as alkyne), and the group consisting of double and triple bonds And hydrocarbons containing two or more bonds selected from the above, and cyclic hydrocarbons such as aromatic hydrocarbons and alicyclic hydrocarbons.

The hydrocarbons are preferably chain hydrocarbons and alicyclic hydrocarbons, more preferably chain hydrocarbons, two paraffin hydrocarbons, olefin hydrocarbons, and two double bonds. More preferred are hydrocarbons (not including triple bonds), and most preferred are paraffinic hydrocarbons.
The chain hydrocarbon includes a straight chain hydrocarbon and a branched chain hydrocarbon.

  In the compounds (ii) and (iii) above, when two or more ether bonds (—O—) are inserted, the ether bonds (—O—) are not adjacent to each other. Accordingly, the compounds (ii) and (iii) do not include compounds having a continuous ether bond (so-called peroxide).

  Further, in the compound (iii), at least one hydrogen atom on the hydrocarbon is more preferably a hydroxyl group (-than a compound in which at least one hydrogen atom on the hydrocarbon is substituted with a carboxyl group (-COOH). Compounds substituted with OH) are preferred. As shown in Table 1, since the carboxyl group binds to menstrual metals and the like, and the inorganic value increases significantly from 150 to 400 or more, the blood modifying agent having a carboxyl group is used at the time of use. This is because the value of IOB exceeds about 0.6, and the affinity with blood cells may be reduced.

The blood modifying agent may preferably be a compound having the following structure.
(I ′) hydrocarbon,
(Ii ′) at least one carbonyl bond (—CO—), at least one ester bond (—COO—), at least one carbonate bond (—OCOO—) and / or between the C—C single bonds of the hydrocarbon; A compound in which at least one ether bond (—O—) is inserted, or (iii ′) at least one carbonyl bond (—CO—), at least one ester bond (— COO-), at least one carbonate bond (-OCOO-) and / or at least one ether bond (-O-), and at least one hydrogen atom on the hydrocarbon is a carboxyl group (-COOH) or A compound substituted with a hydroxyl group (—OH).

  In the compounds (ii ′) and (iii ′) above, when two or more bonds are inserted, that is, a carbonyl bond (—CO—), an ester bond (—COO—), a carbonate bond (—OCOO—) And two or more bonds selected from ether bonds (—O—) are inserted, the bonds are not adjacent to each other, and at least one carbon atom is interposed between the bonds. .

  More preferably, the blood modifying agent is more preferably about 1.8 or less carbonyl bonds (—CO—) and 2 or less ester bonds (—COO—) per 10 carbon atoms in a hydrocarbon. About 1.5 or less of bonds (—OCOO—), about 6 or less of ether bonds (—O—), about 0.8 or less of carboxyl groups (—COOH), and / or hydroxyl groups (—OH) Can be a compound having about 1.2 or less.

The blood modifying agent is more preferably
(A) an ester of a compound having 2 to 4 hydroxyl groups and a compound having 1 carboxyl group,
(B) an ether of a compound having 2 to 4 hydroxyl groups and a compound having 1 hydroxyl group,
(C) an ester of a compound having 2 to 4 carboxyl groups and a compound having 1 hydroxyl group,
(D) Any one selected from the group consisting of a carbonyl bond (—CO—), an ester bond (—COO—), a carbonate bond (—OCOO—) and an ether bond (—O—) is inserted into the hydrocarbon. Compound,
(E) poly C _{3 ~ 6} alkylene glycol or its alkyl ester or alkyl ether, or (F) a chain hydrocarbon,
Can be.
Hereinafter, (A) to (F) will be described in detail.

[(A) Esters of a compound having 2 to 4 hydroxyl groups and a compound having 1 carboxyl group]
(A) An ester of a compound having 2 to 4 hydroxyl groups and a compound having one carboxyl group (hereinafter sometimes referred to as “compound (A)”) has 4, 3, Or an ester of a compound having two hydroxyl groups and a compound having one carboxyl group, and all hydroxyl groups are esterified as long as they are in the range having the above-mentioned IOB, melting point and water solubility. Not necessary.

Examples of the compound having 2 to 4 hydroxyl groups include chain hydrocarbon tetraols such as alkane tetraols such as pentaerythritol, chain hydrocarbon triols such as alkane triols such as glycerin, and the like. Examples include chain hydrocarbon diols such as alkane diols such as glycols. Examples of the compound having one carboxyl group include a compound in which one hydrogen atom on a hydrocarbon is substituted with one carboxyl group (—COOH), for example, a fatty acid.
Examples of the compound (A) include (A ₁ ) an ester of a chain hydrocarbon tetraol and a fatty acid, (A ₂ ) an ester of a chain hydrocarbon triol and a fatty acid, and (A ₃ ) a chain hydrocarbon diol. And esters of fatty acids.

[Ester of (A ₁ ) chain hydrocarbon tetraol and fatty acid]
Examples of the ester of the chain hydrocarbon tetraol and the fatty acid include the following formula (1):
Tetraesters of pentaerythritol and fatty acids of the following formula (2):
Triesters of pentaerythritol and fatty acids of the following formula (3):
Diester of pentaerythritol and fatty acid of the following formula (4):
And monoesters of pentaerythritol and fatty acids.
(In the formula, R ^{1 to} R ⁴ are each a chain hydrocarbon)

As the fatty acid (R ¹ COOH, R ² COOH, R ³ COOH, and R ⁴ COOH) constituting the ester of pentaerythritol and fatty acid, the ester of pentaerythritol and fatty acid has the above-mentioned IOB, melting point and water solubility. as long as it satisfies the requirement is not particularly limited, for example, saturated fatty acids, for example, saturated fatty acids C ₂ -C _30, for example, acetic acid (C ₂₎ (C ₂ indicates the number of carbon atoms, R ¹ C, Corresponding to the carbon number of R ² C, R ³ C or R ⁴ C, the same shall apply hereinafter), propanoic acid (C ₃ ), butanoic acid (C ₄ ) and isomers thereof such as 2-methylpropanoic acid (C ₄ ), pentanoic acid (C ₅₎ and isomers thereof such as 2-methylbutanoic acid (C _5), 2,2-dimethyl propanoic acid (C _5), hexanoic acid (C _6), heptanoic acid (C ₇₎ Octanoic acid (C ₈₎ and isomers thereof, e.g., 2-ethylhexanoic acid (C _8), nonanoic acid (C _9), decanoic acid (C _10), dodecanoic acid (C _12), tetradecanoic acid (C ₁₄₎ Hexadecanoic acid (C ₁₆ ), heptadecanoic acid (C ₁₇ ), octadecanoic acid (C ₁₈ ), eicosanoic acid (C ₂₀ ), docosanoic acid (C ₂₂ ), tetracosanoic acid (C ₂₄ ), hexacosanoic acid (C ₂₆ ), Examples include octacosanoic acid (C ₂₈ ), triacontanoic acid (C ₃₀ ), and the like, and isomers thereof (except those described above).

The fatty acid can also be an unsaturated fatty acid. Examples of the unsaturated fatty acid include C _{3 to} C ₂₀ unsaturated fatty acids such as monounsaturated fatty acids such as crotonic acid (C ₄ ), myristoleic acid (C ₁₄ ), palmitoleic acid (C ₁₆ ), Oleic acid (C ₁₈ ), elaidic acid (C ₁₈ ), vaccenic acid (C ₁₈ ), gadoleic acid (C ₂₀ ), eicosenoic acid (C ₂₀ ), etc., diunsaturated fatty acids such as linoleic acid (C ₁₈ ), Triunsaturated fatty acids such as eicosadienoic acid (C ₂₀ ), such as linolenic acid such as α-linolenic acid (C ₁₈ ) and γ-linolenic acid (C ₁₈ ), pinolenic acid (C ₁₈ ), eleostearic acid, For example, α-eleostearic acid (C ₁₈ ) and β-eleostearic acid (C ₁₈ ), mead acid (C ₂₀ ), dihomo-γ-linolenic acid (C ₂₀ ), eicosatrienoic acid (C ₂₀ ) Etc., tetraunsaturated Fatty acid, e.g., stearidonic acid (C _20), arachidonic acid (C _20), eicosatetraenoic acid (C _20), etc., penta-unsaturated fatty acids, for example, bosseopentaenoic acid (C _18), eicosapentaenoic acid (C ₂₀ ) And the like, as well as these partial hydrogenated products.

The ester of pentaerythritol and fatty acid is an ester of pentaerythritol and a fatty acid derived from a saturated fatty acid, that is, an ester of pentaerythritol and a saturated fatty acid, considering the possibility of modification by oxidation or the like. preferable.
The ester of pentaerythritol and fatty acid is preferably a diester, triester or tetraester, more preferably a triester or tetraester, in order to reduce IOB and make it more hydrophobic. And most preferably tetraesters.

In the tetraester of pentaerythritol and fatty acid, the total number of carbon atoms of the fatty acid constituting the tetraester of pentaerythritol and fatty acid, that is, in the above formula (1), R ¹ C, R ² C, R ³ C and When the total number of carbon atoms in the R ⁴ C portion is 15, IOB is 0.60. Therefore, in the tetraester of pentaerythritol and fatty acid, the IOB satisfies the requirement of about 0 to about 0.6 when the total number of carbon atoms is about 15 or more.
In the tetraester of pentaerythritol and fatty acid, for example, pentaerythritol, hexanoic acid (C ₆ ), heptanoic acid (C ₇ ), octanoic acid (C ₈ ), for example, 2-ethylhexanoic acid (C ₈ ), Examples thereof include tetraesters with nonanoic acid (C ₉ ), decanoic acid (C ₁₀ ) and / or dodecanoic acid (C ₁₂ ).

In the triester of pentaerythritol and fatty acid, the total number of carbon atoms of the fatty acid constituting the triester of pentaerythritol and fatty acid, that is, in the above formula (2), R ¹ C, R ² C and R ³ C moieties When the total number of carbon atoms is 19, IOB is 0.58. Therefore, in the triester of pentaerythritol and fatty acid, the IOB satisfies the requirement of about 0 to about 0.6 when the total number of carbon atoms of the fatty acid is about 19 or more.

In the diester of pentaerythritol and fatty acid, the total number of carbon atoms of the fatty acid constituting the diester of pentaerythritol and fatty acid, that is, the total number of carbon atoms of the R ¹ C and R ² C moieties in the above formula (3) is In the case of 22, the IOB is 0.59. Therefore, in the diester of pentaerythritol and fatty acid, the IOB satisfies the requirement of about 0 to about 0.6 when the total number of carbon atoms of the fatty acid is about 22 or more.

In the monoester of pentaerythritol and fatty acid, the number of carbons of the fatty acid constituting the monoester of pentaerythritol and fatty acid, that is, in the above formula (4), the IOB is 25 when the carbon number of the R ¹ C portion is 25. 0.60. Therefore, in the monoester of pentaerythritol and fatty acid, when the fatty acid has about 25 or more carbon atoms, IOB satisfies the requirement of about 0 to about 0.6.
In the above calculation, the influence of double bonds, triple bonds, iso branches, and tert branches is not taken into consideration.

  As a commercial item of the ester of the said pentaerythritol and a fatty acid, Unistar H-408BRS, H-2408BRS-22 (mixture), etc. (above, NOF Corporation make) are mentioned.

[(A ₂ ) Ester of Chain Hydrocarbon Triol and Fatty Acid]
Examples of the ester of the chain hydrocarbon triol and the fatty acid include the following formula (5):
Triester of glycerin and fatty acid of the following formula (6):
A diester of glycerin and a fatty acid, and the following formula (7):
(Wherein R ^{5 to} R ⁷ are each a chain hydrocarbon)
And monoesters of glycerin and fatty acids.

As the fatty acid (R ⁵ COOH, R ⁶ COOH and R ⁷ COOH) constituting the ester of the glycerin and the fatty acid, as long as the ester of glycerin and the fatty acid satisfies the requirements for the IOB, melting point and water solubility, There is no particular limitation, and examples include fatty acids listed in “(A ₁ ) ester of chain hydrocarbon tetraol and fatty acid”, that is, saturated fatty acid and unsaturated fatty acid, and may be modified by oxidation or the like. In view of the above, an ester of glycerin and a fatty acid derived from a saturated fatty acid, that is, an ester of glycerin and a saturated fatty acid is preferable.
The ester of glycerin and fatty acid is preferably a diester or triester and more preferably a triester in order to reduce IOB and make it more hydrophobic.

The triester of glycerin and a fatty acid is also called a triglyceride. For example, triester of glycerin and octanoic acid (C ₈ ), triester of glycerin and decanoic acid (C ₁₀ ), glycerin and dodecanoic acid (C ₁₂ ) And triesters of glycerin with 2 or 3 fatty acids, and mixtures thereof.

Examples of the triesters of glycerin and two or more fatty acids include triesters of glycerin and octanoic acid (C ₈ ) and decanoic acid (C ₁₀ ), glycerin, octanoic acid (C ₈ ), and decane. Acid (C ₁₀ ) and Dodecanoic acid (C ₁₂ ) Triester, Glycerin, Octanoic acid (C ₈ ), Decanoic acid (C ₁₀ ), Dodecanoic acid (C ₁₂ ), Tetradecanoic acid (C ₁₄ ), Hexadecanoic acid Examples thereof include triesters with (C ₁₆ ) and octadecanoic acid (C ₁₈ ).

As the triester of glycerin and fatty acid, the total number of carbon atoms of the fatty acid constituting the triester of glycerin and fatty acid, that is, R ⁵ C in formula (5) in order to make the melting point about 45 ° C. or less. , R ⁶ C and R ⁷ C moieties preferably have a total carbon number of about 40 or less.

In the triester of glycerin and fatty acid, the total number of carbon atoms of the fatty acid constituting the triester of glycerin and fatty acid, that is, in the formula (5), R ⁵ C, R ⁶ C and R ⁷ C moieties When the total number of carbon atoms is 12, the IOB is 0.60. Therefore, in the triester of the glycerin and the fatty acid, the IOB satisfies the requirement of about 0 to about 0.6 when the total number of carbon atoms of the fatty acid is about 12 or more.
The triester of glycerin and a fatty acid is a so-called fat and is a component that can constitute a human body, and thus is preferable from the viewpoint of safety.

  Commercial products of triesters of glycerin and fatty acids include tricoconut oil fatty acid glyceride, NA36, panacet 800, panaceto 800B and panacet 810S, and tri-C2L oil fatty acid glyceride and tri-CL oil fatty acid glyceride (above, manufactured by NOF Corporation). ) And the like.

The diester of glycerin and fatty acid is also called diglyceride. For example, diester of glycerin and decanoic acid (C ₁₀ ), diester of glycerin and dodecanoic acid (C ₁₂ ), glycerin and hexadecanoic acid (C ₁₆ ) Examples include diesters, diesters of glycerin and two fatty acids, and mixtures thereof.
In the diester of glycerin and fatty acid, the total number of carbon atoms of the fatty acid constituting the diester of glycerin and fatty acid, that is, the total number of carbon atoms of the R ⁵ C and R ⁶ C moieties in the formula (6) is 16. The IOB is 0.58. Therefore, in the diester of glycerin and fatty acid, the IOB satisfies the requirement of about 0 to about 0.6 when the total number of carbon atoms of the fatty acid is about 16 or more.

The monoester of the glycerin and the fatty acid is also referred to as monoglyceride, and examples thereof include glycerin octadecanoic acid (C ₁₈ ) monoester, glycerin docosanoic acid (C ₂₂ ) monoester, and the like.
In the monoester of glycerin and fatty acid, the number of carbon atoms of the fatty acid constituting the monoester of glycerin and fatty acid, that is, when the carbon number of the R ⁵ C moiety in the formula (7) is 19, the IOB is 0.59. It becomes. Therefore, in the monoester of the glycerin and the fatty acid, when the carbon number of the fatty acid is about 19 or more, the IOB satisfies the requirement of about 0 to about 0.6.

[Ester of (A ₃ ) chain hydrocarbon diol and fatty acid]
Examples of the ester of the chain hydrocarbon diol and the fatty acid include C _{2 to} C ₆ chain hydrocarbon diols such as C _{2 to} C ₆ glycols such as ethylene glycol, propylene glycol, butylene glycol, and pliers. Examples thereof include monoesters or diesters of lene glycol or hexylene glycol and fatty acids.

Specifically, as the ester of the chain hydrocarbon diol and the fatty acid, for example, the following formula (8):
R ⁸ COOC _k H _2k OCOR ⁹ (8)
(Wherein k is an integer from 2 to 6 and R ⁸ and R ⁹ are each a chain hydrocarbon)
A diester of a C ₂ -C ₆ glycol with a fatty acid and the following formula (9):
R ⁸ COOC _k H _2k OH (9)
(Wherein k is an integer from 2 to 6 and R ⁸ is a chain hydrocarbon)
And monoesters of C ₂ -C ₆ glycols and fatty acids.

In the ester of C ₂ -C ₆ glycol and fatty acid, the fatty acid to be esterified (corresponding to R ⁸ COOH and R ⁹ COOH in formula (8) and formula (9)) is C ₂ -C ₆ glycol. And esters of fatty acids are not particularly limited as long as they satisfy the above requirements for IOB, melting point and water solubility, and are listed in, for example, “(A ₁ ) ester of chain hydrocarbon tetraol and fatty acid”. Fatty acids, that is, saturated fatty acids and unsaturated fatty acids, and saturated fatty acids are preferred in consideration of the possibility of modification by oxidation or the like.

In the diester of butylene glycol (k = 4) and a fatty acid represented by the formula (8), when the total number of carbon atoms in the R ⁸ C and R ⁹ C moieties is 6, IOB is 0.6. Therefore, in the diester of butylene glycol (k = 4) and fatty acid represented by formula (8), when the total number of carbon atoms is about 6 or more, IOB satisfies the requirement of about 0 to about 0.6. Moreover, in the monoester of ethylene glycol (k = 2) and a fatty acid represented by the formula (9), when the carbon number of the R ⁸ C portion is 12, the IOB is 0.57. Therefore, in the monoester of ethylene glycol (k = 2) and a fatty acid represented by formula (9), when the fatty acid has about 12 or more carbon atoms, the IOB satisfies the requirement of about 0 to about 0.6. .

The ester of a C ₂ -C ₆ glycol and fatty acids, in consideration of the potential for degradation by oxidation and the like, derived from saturated fatty acids, esters of C ₂ -C ₆ glycol and fatty acid, Nachi Suwa, C ₂ it is preferable -C ₆ glycol and an ester of saturated fatty acids.

As the ester of a C ₂ -C ₆ glycol and fatty acid, to reduce the IOB, in order to more hydrophobic, from large glycol carbon number, esters of glycols and fatty acids, for example, butylene glycol It is preferably an ester of glycol and fatty acid derived from pentylene glycol or hexylene glycol.
Furthermore, the ester of the C ₂ -C ₆ glycol and the fatty acid is preferably a diester in order to reduce IOB and make it more hydrophobic.
Examples of commercial products of esters of the C ₂ -C ₆ glycols with fatty acids, for example, COMPOL BL, COMPOL BS (products of NOF Corporation) and the like.

[(B) an ether of a compound having 2 to 4 hydroxyl groups and a compound having 1 hydroxyl group]
(B) The ether of a compound having 2 to 4 hydroxyl groups and a compound having one hydroxyl group (hereinafter sometimes referred to as “compound (B)”) has 4, 3, Or an ether of a compound having two hydroxyl groups and a compound having one hydroxyl group, so long as it is in the range having the above-mentioned IOB, melting point and water solubility, all hydroxyl groups are etherified. Not necessary.

Examples of the compound having 2 to 4 hydroxyl groups include those listed in “Compound (A)”, for example, pentaerythritol, glycerin, and glycol.
Examples of the compound having one hydroxyl group include a compound in which one hydrogen atom of a hydrocarbon is substituted with one hydroxyl group (—OH), for example, an aliphatic monohydric alcohol, for example, saturated Examples include aliphatic monohydric alcohols and unsaturated aliphatic monohydric alcohols.

Examples of the saturated aliphatic monohydric alcohol include C _{1 to} C ₂₀ saturated aliphatic monohydric alcohols such as methyl alcohol (C ₁ ) (C ₁ represents the number of carbon atoms, the same shall apply hereinafter), ethyl alcohol ( C _2), propyl alcohol (C ₃₎ and isomers thereof, for example, isopropyl alcohol (C _3), butyl alcohol (C ₄₎ and isomers thereof, for example, sec- butyl alcohol (C ₄₎ and tert- butyl alcohol (C ₄ ), pentyl alcohol (C ₅ ), hexyl alcohol (C ₆ ), heptyl alcohol (C ₇ ), octyl alcohol (C ₈ ) and isomers thereof such as 2-ethylhexyl alcohol (C ₈ ), nonyl alcohol (C ₉ ), decyl alcohol (C ₁₀ ), dodecyl alcohol (C ₁₂ ), tetradecyl al Cole (C ₁₄ ), Hexadecyl alcohol (C ₁₆ ), Hepradecyl alcohol (C ₁₇ ), Octadecyl alcohol (C ₁₈ ), and Eicosyl alcohol (C ₂₀ ), and their unlisted isomers It is done.
Examples of the unsaturated aliphatic monohydric alcohol include those obtained by substituting one of the C—C single bonds of the saturated aliphatic monohydric alcohol with a C═C double bond, such as oleyl alcohol. It is commercially available from Shin Nippon Rika Co., Ltd. under the names of the Rica Coal series and the Angelo All series.

Examples of the compound (B) include (B ₁ ) ethers of chain hydrocarbon tetraols and aliphatic monohydric alcohols, such as monoethers, diethers, triethers and tetraethers, preferably diethers, triethers and tetraethers. Ethers, more preferably triethers and tetraethers, and even more preferably tetraethers, ethers of (B ₂ ) chain hydrocarbon triols and aliphatic monohydric alcohols, such as monoethers, diethers and triethers, preferably diethers And triethers, and more preferably triethers, and ethers of (B ₃ ) chain hydrocarbon diols and aliphatic monohydric alcohols, such as monoethers and diethers, and preferably diethers.

Examples of the ether of the chain hydrocarbon tetraol and the aliphatic monohydric alcohol include, for example, the following formulas (10) to (13):
(In the formula, R ^{10 to} R ¹³ are each a chain hydrocarbon.)
And tetraethers, triethers, diethers and monoethers of pentaerythritol and aliphatic monohydric alcohols.

Examples of the ether of the chain hydrocarbon triol and the aliphatic monohydric alcohol include the following formulas (14) to (16):
(In the formula, R ^{14 to} R ¹⁶ are each a chain hydrocarbon.)
And triethers, diethers and monoethers of glycerin and aliphatic monohydric alcohols.

Examples of ethers of the chain hydrocarbon diol and the aliphatic monohydric alcohol include the following formula (17):
R ¹⁷ OC _n H _2n OR ¹⁸ (17)
(Wherein n is an integer from 2 to 6 and R ¹⁷ and R ¹⁸ are each a chain hydrocarbon)
A diether of a C ₂ -C ₆ glycol and an aliphatic monohydric alcohol, and the following formula (18):
R ¹⁷ OC _n H _2n OH (18)
(Wherein n is an integer from 2 to 6 and R ¹⁷ is a chain hydrocarbon)
And a monoether of a C ₂ -C ₆ glycol and an aliphatic monohydric alcohol.

In the tetraether of pentaerythritol and aliphatic monohydric alcohol, the total number of carbon atoms of the aliphatic monohydric alcohol constituting the tetraether of pentaerythritol and aliphatic monohydric alcohol, that is, in the above formula (10), When the total number of carbon atoms in R ¹⁰ , R ¹¹ , R ¹² and R ¹³ is 4, IOB is 0.44. Therefore, in the tetraether of pentaerythritol and aliphatic monohydric alcohol, the IOB satisfies the requirement of about 0 to about 0.6 when the total number of carbon atoms of the aliphatic monohydric alcohol is about 4 or more.

In the triether of pentaerythritol and aliphatic monohydric alcohol, the total number of carbon atoms of the aliphatic monohydric alcohol constituting the triether of pentaerythritol and aliphatic monohydric alcohol, that is, in the above formula (11), When the total number of carbon atoms in R ¹⁰ , R ¹¹ and R ¹² is 9, IOB is 0.57. Therefore, in the triether of pentaerythritol and aliphatic monohydric alcohol, when the total number of carbon atoms of the aliphatic monohydric alcohol is about 9 or more, IOB satisfies the requirement of about 0 to about 0.6.

In the diether of pentaerythritol and aliphatic monohydric alcohol, the total number of carbon atoms of the aliphatic monohydric alcohol constituting the diether of pentaerythritol and aliphatic monohydric alcohol, that is, in the formula (12), R ¹⁰ When the total number of carbon atoms in the R ¹¹ portion is 15, the IOB is 0.60. Therefore, in the diether of pentaerythritol and aliphatic monohydric alcohol, the IOB satisfies the requirement of about 0 to about 0.6 when the total number of carbon atoms of the aliphatic monohydric alcohol is about 15 or more.

In the monoether of pentaerythritol and aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the monoether of pentaerythritol and aliphatic monohydric alcohol, that is, in the above formula (13), R ¹⁰ When the number of carbon atoms in the portion is 22, the IOB is 0.59. Therefore, in the monoether of pentaerythritol and aliphatic monohydric alcohol, when the aliphatic monohydric alcohol has about 22 or more carbon atoms, the IOB satisfies the requirement of about 0 to about 0.6.

In the triether of glycerin and aliphatic monohydric alcohol, the total number of carbon atoms of the aliphatic monohydric alcohol constituting the triether of glycerin and aliphatic monohydric alcohol, that is, in the formula (14), R ^When the total number of carbon atoms in the ¹⁴ , R ¹⁵ and R ¹⁶ parts is 3, the IOB is 0.50. Therefore, in the above triether of glycerin and aliphatic monohydric alcohol, when the total number of carbon atoms of the aliphatic monohydric alcohol is about 3 or more, IOB satisfies the requirement of about 0 to about 0.6.

In the diether of glycerin and aliphatic monohydric alcohol, the total number of carbon atoms of the aliphatic monohydric alcohol constituting the diether of glycerin and aliphatic monohydric alcohol, that is, in the formula (15), R ¹⁴ and R ¹⁵ When the total number of carbon atoms in the portion is 9, the IOB is 0.58. Therefore, in the diether of glycerin and aliphatic monohydric alcohol, when the total number of carbon atoms of the aliphatic monohydric alcohol is about 9 or more, IOB satisfies the requirement of about 0 to about 0.6.

In the monoether of glycerin and aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the monoether of glycerin and aliphatic monohydric alcohol, that is, the carbon of R ¹⁴ moiety in the formula (16). When the number is 16, the IOB is 0.58. Therefore, in the monoether of the glycerin and the aliphatic monohydric alcohol, when the aliphatic monohydric alcohol has about 16 or more carbon atoms, the IOB satisfies the requirement of about 0 to about 0.6.

In the diether of butylene glycol (n = 4) and aliphatic monohydric alcohol represented by the formula (17), when the total number of carbon atoms in the R ¹⁷ and R ¹⁸ parts is 2, the IOB is 0.33. . Therefore, in the diether of butylene glycol (n = 4) and the aliphatic monohydric alcohol represented by the formula (17), when the total number of carbon atoms of the aliphatic monohydric alcohol is 2 or more, the IOB is about 0 to about Meet the requirement of 0.6. Further, in the monoether of ethylene glycol (n = 2) and aliphatic monohydric alcohol represented by the formula (18), when the number of carbon atoms in the R ¹⁷ portion is 8, the IOB is 0.60. Therefore, in the monoether of ethylene glycol (n = 2) and aliphatic monohydric alcohol represented by formula (18), when the aliphatic monohydric alcohol has about 8 or more carbon atoms, the IOB is about 0 to 0. Meet the requirement of about 0.6.

  Compound (B) is produced by dehydration condensation of a compound having 2 to 4 hydroxyl groups and a compound having 1 hydroxyl group such as an aliphatic monohydric alcohol in the presence of an acid catalyst. can do.

[(C) an ester of a compound having 2 to 4 carboxyl groups and a compound having 1 hydroxyl group]
(C) An ester of a compound having 2 to 4 carboxyl groups and a compound having one hydroxyl group (hereinafter sometimes referred to as “compound (C)”) is 4, 3 or As long as an ester of a compound having two carboxyl groups and a compound having one hydroxyl group is included and has the above-mentioned IOB, melting point and water solubility, all the carboxyl groups are not esterified. Also good.

  Examples of the compound having 2 to 4 carboxyl groups include chain hydrocarbons having 2 to 4 carboxyl groups, such as chain hydrocarbon dicarboxylic acids such as alkanedicarboxylic acids such as ethanedioic acid. , Propanedioic acid, butanedioic acid, pentanedioic acid, hexanedioic acid, heptanedioic acid, octanedioic acid, nonanedioic acid and decanedioic acid, chain hydrocarbon tricarboxylic acids such as alkanetricarboxylic acid such as propane Acids, butanetriacids, pentanetriacids, hexanetriacids, heptanetriacids, octanetriacids, nonanetriacids and decanetriacids, and chain hydrocarbon tetracarboxylic acids such as alkanetetracarboxylic acids such as butanetetra Acid, pentanetetraacid, hexanetetraacid, heptanetetraacid, octanetetraacid, nonanetetraacid and decanetetraacid And the like.

The compound having 2 to 4 carboxyl groups has 2 to 4 carboxyl groups such as hydroxy acid having 2 to 4 carboxyl groups, such as malic acid, tartaric acid, citric acid, and isocitric acid. Alkoxy acids having, for example, O-acetylcitric acid, and oxo acids having 2 to 4 carboxyl groups.
Examples of the compound having one hydroxyl group include those listed in the section of “Compound (B)”, for example, aliphatic monohydric alcohols.

As the compound (C), (C ₁ ) an ester of a chain hydrocarbon tetracarboxylic acid having 4 carboxyl groups, a hydroxy acid, an alkoxy acid or an oxo acid and an aliphatic monohydric alcohol, such as a monoester, Diesters, triesters and tetraesters, preferably diesters, triesters and tetraesters, more preferably triesters and tetraesters, and even more preferably tetraesters, (C ₂ ) chain hydrocarbon tricarboxylic acids having three carboxyl groups Esters of acids, hydroxy acids, alkoxy acids or oxo acids with aliphatic monohydric alcohols, such as monoesters, diesters and triesters, preferably diesters and triesters, and more preferably triesters, and (C ₃ ) 2 pieces Chain hydrocarbon dicarboxylic acids having a carboxyl group, hydroxy acids, esters of alkoxy acids or oxoacids, and aliphatic monohydric alcohols, for example, mono- and diesters, and the like, preferably a diester.
Examples of the compound (C) include dioctyl adipate, diisostearyl malate, tributyl citrate, tributyl O-acetylcitrate and the like, and are commercially available.

[(D) The hydrocarbon is selected from the group consisting of an ether bond (—O—), a carbonyl bond (—CO—), an ester bond (—COO—), and a carbonate bond (—OCOO—). Compound with one inserted]
(D) The hydrocarbon has any one selected from the group consisting of an ether bond (—O—), a carbonyl bond (—CO—), an ester bond (—COO—), and a carbonate bond (—OCOO—). The inserted compound (hereinafter sometimes referred to as “compound (D)”) includes (D ₁ ) an ether of an aliphatic monohydric alcohol and an aliphatic monohydric alcohol, (D ₂ ) a dialkyl ketone, (D ₃ ) Esters of fatty acids and aliphatic monohydric alcohols, and (D ₄ ) dialkyl carbonates.

[(D ₁ ) Ether of aliphatic monohydric alcohol and aliphatic monohydric alcohol]
Examples of the ether of the aliphatic monohydric alcohol and the aliphatic monohydric alcohol include the following formula (19):
R ¹⁹ OR ²⁰ (19)
(In the formula, R ¹⁹ and R ²⁰ are each a chain hydrocarbon)
The compound which has is mentioned.

As the aliphatic monohydric alcohol constituting the ether (corresponding to R ¹⁹ OH and R ²⁰ OH in the formula (19)), the ether satisfies the requirements of the IOB, melting point and water solubility. There is no particular limitation, and examples thereof include aliphatic monohydric alcohols listed in the section of “Compound (B)”.

In the ether of an aliphatic monohydric alcohol and an aliphatic monohydric alcohol, the total number of carbon atoms of the aliphatic monohydric alcohol constituting the ether, that is, the carbon number of R ¹⁹ and R ²⁰ in the above formula (19). Since the IOB is 0.50 when the sum of the two is 2, the IOB requirement is satisfied if the total number of carbon atoms is about 2 or more. However, when the total number of carbon atoms is about 6, the water solubility is as high as about 2 g, which is problematic from the viewpoint of vapor pressure. In order to satisfy the requirement of water solubility of about 0.05 g or less, the total number of carbon atoms is preferably about 8 or more.

[(D ₂ ) dialkylketone]
As the dialkyl ketone, the following formula (20):
R ²¹ COR ²² (20)
(Wherein R ²¹ and R ²² are each an alkyl group)
The compound which has is mentioned.

In the dialkyl ketone, since the IOB is 0.54 when the total number of carbon atoms of R ²¹ and R ²² is 5, the above IOB requirement is satisfied if the total number of carbon atoms is about 5 or more. However, when the total number of carbon atoms is about 5, the water solubility is as high as about 2 g. Therefore, in order to satisfy the requirement that the water solubility is about 0.05 g or less, the total number of carbon atoms is preferably about 8 or more. In consideration of the vapor pressure, the carbon number is preferably about 10 or more, and more preferably about 12 or more.
When the total number of carbon atoms is about 8, for example, 5-nonanone has a melting point of about −50 ° C. and a vapor pressure of about 230 Pa at 20 ° C.
In addition to being commercially available, the dialkyl ketone can be obtained by a known method, for example, by oxidizing a secondary alcohol with chromic acid or the like.

[(D ₃ ) ester of fatty acid and aliphatic monohydric alcohol]
Examples of the ester of the fatty acid and the aliphatic monohydric alcohol include the following formula (21):
R ²³ COOR ²⁴ (21)
(Wherein R ²³ and R ²⁴ are each a chain hydrocarbon)
The compound which has is mentioned.

Examples of the fatty acid constituting the ester (corresponding to R ²³ COOH in the formula (21)) include, for example, the fatty acids listed in “(A ₁ ) ester of chain hydrocarbon tetraol and fatty acid”, Saturated fatty acids or unsaturated fatty acids are mentioned, and saturated fatty acids are preferred in consideration of the possibility of modification by oxidation or the like. Examples of the aliphatic monohydric alcohol constituting the ester (corresponding to R ²⁴ OH in formula (21)) include the aliphatic monohydric alcohols listed in the section “Compound (B)”.

In the ester of the fatty acid and the aliphatic monohydric alcohol, the total number of carbon atoms of the fatty acid and the aliphatic monohydric alcohol, that is, the total number of carbon atoms in the R ²³ C and R ²⁴ portions in the formula (21) is 5 In this case, the IOB is 0.60. Therefore, in the ester of the fatty acid and the aliphatic monohydric alcohol, when the total number of carbon atoms in the R ²³ C and R ²⁴ parts is about 5 or more, the IOB requirements Meet. However, for example, butyl acetate having a total of 6 carbon atoms has a high vapor pressure of over 2000 Pa. Therefore, considering the vapor pressure, the total number of carbon atoms is preferably about 12 or more. In addition, if the total number of carbon atoms is about 11 or more, the water solubility can satisfy the requirement of about 0.05 g or less.

Examples of the ester of the fatty acid and the aliphatic monohydric alcohol include, for example, an ester of dodecanoic acid (C ₁₂ ) and dodecyl alcohol (C ₁₂ ), tetradecanoic acid (C ₁₄ ), and dodecyl alcohol (C ₁₂ ). Examples of commercially available esters of fatty acids and aliphatic monohydric alcohols include Electol WE20 and Electol WE40 (manufactured by NOF Corporation).

[(D ₄ ) dialkyl carbonate]
As the dialkyl carbonate, the following formula (22):
R ²⁵ OC (= O) OR ²⁶ (22)
(Wherein R ²⁵ and R ²⁶ are each an alkyl group)
The compound which has is mentioned.

In the above dialkyl carbonate, since the IOB is 0.57 when the total number of carbon atoms of R ²⁵ and R ²⁶ is 6, if the total number of carbon atoms of R ²⁵ and R ²⁶ is about 6 or more, Satisfy requirements.
In consideration of water solubility, the total number of carbon atoms of R ²⁵ and R ²⁶ is preferably about 7 or more, and more preferably about 9 or more.
In addition to being commercially available, the dialkyl carbonate can be synthesized by a reaction between phosgene and an alcohol, a reaction between a chlorinated formate and an alcohol or an alcoholate, and a reaction between silver carbonate and an alkyl iodide.

[(E) poly C _{2 ~ 6} alkylene glycol or an ester or ether,]
The poly C _{2 ~ 6} alkylene glycol or an ester or ether, (hereinafter sometimes referred to as compound (E)) The (E ₁₎ poly C _{2 ~ 6} alkylene glycol, (E ₂₎ poly C _{2 ~ 6} esters of alkylene glycols with fatty acids, (E ₃₎ poly C _{2 ~ 6} alkylene glycol and an aliphatic monohydric ether alcohols, (E ₄₎ poly C _{2 ~ 6} alkylene glycol and a chain hydrocarbon tetracarboxylic acid , esters of chain hydrocarbon tricarboxylic acid or chain hydrocarbon dicarboxylic acid, and (E _5), and poly C _{2 ~ 6} alkylene glycol and a chain hydrocarbon tetraol, chain hydrocarbon triol or chain hydrocarbon, And ether with hydrogen diol. This will be described below.

[(E ₁₎ poly C _{2 ~ 6} alkylene glycol]
(E ₁₎ to the poly C _{2 ~ 6} alkylene glycol, as well as homopolymers of a single glycol, 2 or more glycols copolymers and random polymers are also included. The glycol species, C 2 _{~ 6} alkylene glycol, i.e., ethylene glycol, propylene glycol, butylene glycol, pentylene glycol or hexylene glycol. As the glycol species, from the viewpoint of lowering the IOB poly C _{2 ~ 6} alkylene glycol, propylene glycol, butylene glycol, preferably a pentylene glycol or hexylene glycol, butylene glycol, pentylene glycol or hexylene glycol It is more preferable that

In this specification, "poly C _{2 ~ 6} alkylene glycol", C 2 _{~ 6} alkylene glycol, i.e., ethylene glycol, propylene glycol, butylene glycol, is selected from the group consisting of pentylene glycol and hexylene glycol It means any one kind of homopolymer, two or more kinds of copolymers selected from the above group, or two or more kinds of random polymers selected from the above group.

When the poly C _{2 ~ 6} alkylene glycol is a homopolymer, poly C _{2 ~ 6} alkylene glycol, the following equation (23):
_{HO- (C m H 2m O)} n -H (23)
Is represented by

The present inventors have confirmed that polyethylene glycol (corresponding to m = 2 in formula (23)) is about 0 to about when n ≧ 45 (approximately over 2,000 molecular weight). Although the IOB requirement of 0.60 was met, the water solubility requirement was not met even when the molecular weight exceeded 4,000. Therefore, (E ₁₎ to the poly-C _{2 ~ 6} alkylene glycols, homopolymers of ethylene glycol is considered to not contain ethylene glycol as a copolymer or random polymer with another glycol, (E ₁₎ poly C It should be included in the _{2 to 6} alkylene glycol.

Thus, the homopolymer of formula (23) may include a homopolymer of propylene glycol, butylene glycol, pentylene glycol or hexylene glycol.
From the above, in formula (23), m is about 3 to about 6, more preferably about 4 to about 6, and n is 1 or more.

In the above formula (23), the value of n, poly C _{2 ~ 6} alkylene glycol, and from about 0 to about 0.60 IOB, and a melting point below about 45 ° C., in water 100g of 25 ° C., about 0. It is such a value that it has a water solubility of not more than 05 g.
For example, when Formula (23) is polypropylene glycol (m = 3), when n = 12, the IOB is 0.58. Therefore, when Formula (23) is polypropylene glycol (m = 3), the above IOB requirement is satisfied when m ≧ about 12.
When the formula (21) is polybutylene glycol (m = 4), the IOB is 0.57 when n = 7. Therefore, when the formula (23) is polybutylene glycol (m = 4), the above IOB requirement is satisfied when n ≧ about 7.

From the standpoint of OB, melting point and water solubility, the weight average molecular weight of the poly C _4-6 alkylene glycol is preferably about 200 to about 10,000, more preferably about 250 to about 8,000, and more preferably about It is in the range of 250 to about 5,000.
Further, from the viewpoint of OB, melting point and water solubility, the weight average molecular weight of the poly C ₃ alkylene glycol, ie, polypropylene glycol, is preferably about 1,000 to about 10,000, more preferably about 3,000 to about 8. , And more preferably in the range of about 4,000 to about 5,000. This is because, when the weight average molecular weight is less than about 1,000, the water solubility does not satisfy the requirement, and the higher the weight average molecular weight, the more the absorber transfer speed and the whiteness of the top sheet tend to be improved.

Examples of commercial products of the poly C _{2 ~ 6} alkylene glycol, e.g., UNIOL (TM) D-1000, D-1200 , D-2000, D-3000, D-4000, PB-500, PB-700, PB- 1000 and PB-2000 (above, manufactured by NOF Corporation).

[(E ₂₎ an ester of a poly C _{2 ~ 6} alkylene glycol and fatty acid]
The ester of a poly-C _{2 ~ 6} alkylene glycol and a fatty acid, one or both of the OH-terminated poly C _{2 ~ 6} alkylene glycol described in the section "(E ₁₎ poly C _{2 ~ 6} alkylene glycol" is Those that are esterified with fatty acids, that is, monoesters and diesters are mentioned.

In esters of poly C _{2 ~ 6} alkylene glycol and fatty acid, the fatty acid to be esterified, for example, fatty acids listed in the "(A ₁₎ chain hydrocarbon tetraols and esters of fatty acids", i.e., saturated Fatty acids or unsaturated fatty acids can be mentioned, and saturated fatty acids are preferred in consideration of the possibility of modification by oxidation or the like.
Examples of commercial products of esters of the poly C _{3 ~ 6} alkylene glycols with fatty acids, for example, Will Bright cp9 (NOF Corporation) and the like.

[(E ₃₎ poly C _{2 ~ 6} alkylene glycol and ethers and aliphatic monohydric alcohol]
The ethers of the poly C _{2 ~ 6} alkylene glycol and an aliphatic monohydric alcohol, one OH-terminated poly C _{2 ~ 6} alkylene glycol described in the section "(E ₁₎ poly C _{2 ~ 6} alkylene glycol" Or both are etherified with aliphatic monohydric alcohols, ie monoethers and diethers.
In an ether of a poly C _{2 ~ 6} alkylene glycol and an aliphatic monohydric alcohol, the aliphatic monohydric alcohol to be etherified, for example, aliphatic monohydric alcohols listed for "compound (B)" Can be mentioned.

[(E ₄₎ and poly C _{2 ~ 6} alkylene glycol and a chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid or ester of a chain hydrocarbon dicarboxylic acid,]
And the poly C _{2 ~ 6} alkylene glycol and a chain hydrocarbon tetracarboxylic acid, in an ester of a chain hydrocarbon tricarboxylic acid or chain hydrocarbon dicarboxylic acids, as the poly C _{2 ~ 6} alkylene glycol to be esterified, poly C _{2 ~ 6} alkylene glycol described in the section "(E ₁₎ poly C _{2 ~ 6} alkylene glycol" may be mentioned. Examples of the chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid, and chain hydrocarbon dicarboxylic acid to be esterified include those described in the section of “Compound (C)”.

Esters of the poly C _{2 ~ 6} alkylene glycol and a chain hydrocarbon tetracarboxylic acid, and chain hydrocarbon tricarboxylic acid or chain hydrocarbon dicarboxylic acid, In addition, commercially available, chain hydrocarbon tetracarboxylic acid , chain hydrocarbon tricarboxylic acid or chain hydrocarbon dicarboxylic acid, a C 2 _{~ 6} alkylene glycol, can be prepared by polycondensation under known conditions.

[(E ₅₎ and poly C _{2 ~ 6} alkylene glycol and a chain hydrocarbon tetraol, chain hydrocarbon triol or an ether of a chain hydrocarbon diol,]
And the poly C _{2 ~ 6} alkylene glycol and a chain hydrocarbon tetraol, chain hydrocarbon triol or in an ether of a chain hydrocarbon diol, as the poly C _{2 ~ 6} alkylene glycol to be etherified, "(E ₁₎ poly C _{2 ~ 6} alkylene glycol is described in the section of the poly-C _{2 ~ 6} alkylene glycol "it may be mentioned. The chain hydrocarbon tetraol, chain hydrocarbon triol, and chain hydrocarbon diol to be etherified include those described in the section of “Compound (A)”, for example, pentaerythritol, glycerin, and glycol. Is mentioned.

The poly and C _{2 ~ 6} alkylene glycol and a chain hydrocarbon tetraol, chain hydrocarbon triol or as ethers of commercial products of the chain hydrocarbon diols, are, for example, UNILUBE (TM) 5TP-300KB, and Uniol (Trademark) TG-3000 and TG-4000 (made by NOF Corporation) are mentioned.
Unilube (trademark) 5TP-300KB is a compound obtained by polycondensation of 1 mol of pentaerythritol with 65 mol of propylene glycol and 5 mol of ethylene glycol. Its IOB is 0.39, and its melting point is less than 45 ° C. Yes, and the water solubility was less than 0.05 g.

Uniol ™ TG-3000 is a compound obtained by polycondensation of 1 mol of glycerin and 50 mol of propylene glycol, its IOB is 0.42, its melting point is less than 45 ° C, and its water solubility is 0.05 g. And the weight average molecular weight was about 3,000.
Uniol ™ TG-4000 is a compound obtained by polycondensation of 70 mol of propylene glycol with 1 mol of glycerin, its IOB is 0.40, its melting point is less than 45 ° C., and its water solubility is 0.05 g. And the weight average molecular weight was about 4,000.

And the poly C _{2 ~ 6} alkylene glycol and a chain hydrocarbon tetraol, chain hydrocarbon triol or an ether of a chain hydrocarbon diol also chain hydrocarbon tetraol, chain hydrocarbon triol or chain, to Jo hydrocarbon diols, C 2 _{~ 6} alkylene glycol, can be prepared by polycondensation under known conditions.

[(F) chain hydrocarbon]
Since the chain hydrocarbon has an inorganic value of 0, the IOB is 0 and the water solubility is almost 0 g. It can be included in the agent. Examples of the chain hydrocarbon include (F ₁ ) chain alkanes such as straight chain alkanes and branched chain alkanes. For example, in the case of straight chain alkanes, the melting point is about 45 ° C. or less. In general, those having 22 or less carbon atoms are included. Moreover, when the vapor pressure is taken into consideration, those having 13 or more carbon atoms are generally included. In the case of a branched chain alkane, the melting point may be lower at the same number of carbons than that of a straight chain alkane. As a commercial item of the above-mentioned hydrocarbon, for example, Pearl Ream 6 (NOF Corporation) can be mentioned.

  The blood modifying agent will be discussed in detail together with the examples, and is considered to have a mechanism for lowering the viscosity and surface tension of blood. Compared with normal blood, menstrual blood to be absorbed by the absorbent article contains proteins such as the endometrial wall. Cheap. Therefore, menstrual blood to be absorbed by the absorbent article tends to be highly viscous, and when the top sheet is a non-woven fabric, menstrual blood is likely to clog between the fibers, and the wearer is likely to feel a stickiness, and Menstrual blood diffuses on the surface of the top sheet, making it easier to leak.

  In the absorbent article of the present disclosure, the top sheet contains a blood modifying agent that is considered to have a mechanism for lowering the viscosity and surface tension of blood, so that menstrual blood is not easily clogged between the fibers of the top sheet. Blood can be quickly transferred from the top sheet to the absorber. Further, in the absorbent article of the present disclosure, the blood modifying agent has a melting point of about 45 ° C. or less, so that it is about 30 to about 30 ° C. regardless of whether it is liquid or solid at room temperature (25 ° C.). It is considered that when it comes into contact with a body fluid at 40 ° C., it liquefies (or is a liquid) and is easily dissolved in the body fluid.

  Furthermore, a blood modifying agent having an IOB of about 0 to about 0.60 is highly organic and easily enters between blood cells, which stabilizes the blood cells and makes it difficult to form a monetary structure on the blood cells. It is considered possible. It is considered that the above-mentioned modifying agent stabilizes blood cells and makes it difficult to form a monetary structure on the blood cells, so that the absorbent body can easily absorb menstrual blood. For example, it is known that, in an absorbent article containing an acrylic superabsorbent polymer, so-called SAP, when menstrual blood is absorbed, the blood cells that have been collected cover the surface of the SAP, making it difficult for the SAP to exhibit absorption performance. It is considered that SAP stabilizes blood cells and can easily exhibit absorption performance. In addition, it is considered that the blood modifying agent having a high affinity for red blood cells protects the red blood cell membrane, so that the red blood cells are hardly destroyed.

  When the blood modifying agent is applied to the material, for example, when the top sheet is a non-woven fabric or an apertured film made of a synthetic resin, these are made hydrophilic by being coated or mixed with a hydrophilic agent. Preferably it has been treated. If the original material is hydrophilic, then it has an IOB of about 0 to about 0.60 and is coated with a highly organic and lipophilic modifier, so that the lipophilic region, the hydrophilic region, Will coexist sparsely. Thereby, it is considered that a certain absorption performance can be exhibited for menstrual blood composed of a hydrophilic component (plasma and the like) and a lipophilic component (blood cell and the like).

  The blood modifying agent preferably has a weight average molecular weight of about 2,000 or less, and more preferably has a weight average molecular weight of 1,000 or less. This is because when the weight average molecular weight increases, it becomes difficult to lower the viscosity of the blood modifying agent to a viscosity suitable for coating, and there is a case where the blood modifying agent should be diluted with a solvent. Further, when the number average molecular weight is increased, the blood modifying agent is tacky, which may cause discomfort to the wearer.

(Second Embodiment)
A second embodiment of the present invention will be described with reference to the drawings, but the present invention is not limited to what is described in the drawings. In addition, the same code | symbol is attached | subjected to the part which is common in the 1st Embodiment of this invention, and a different part from the 1st Embodiment of this invention is mainly demonstrated.

  FIG. 3 is a plan view of an absorbent article according to the second embodiment of the present invention. The absorbent article 1B of the second embodiment has a region 26 (in the absorbent article 1B of the second embodiment, the longitudinal direction of the absorbent article 1B) that faces the discharge port through which the menstrual blood of the wearer is discharged when worn. And a central region in the width direction), and the top sheet 2 includes an annular inner pressing groove 21B that is longer in the longitudinal direction than the width direction and an annular outer pressing groove 22B that surrounds the inner pressing groove 21B. The inner pressing groove 21B and the outer pressing groove 22B are formed by compressing the main body portion 6 in the thickness direction by heat embossing. The inner pressing groove 21B and the outer pressing groove 22B block the spread of menstrual blood in the width direction and efficiently transfer menstrual blood to the absorbent body 4. Furthermore, the inner pressing groove 21 </ b> B and the outer pressing groove 22 </ b> B increase the rigidity of the absorbent article 1 </ b> B and increase the integrity of the top sheet 2, the absorbent body 4, and the back sheet 3.

  The top sheet 2 has a blood modifying agent application region 8B to which a blood modifying agent is applied. The blood modifying agent application region 8B is provided inside the outer pressing groove 22B, and is provided on the top sheet 2 so that the inner pressing groove 21B is included in the blood modifying agent region. As described above, the blood modifying agent lowers the viscosity and surface tension of menstrual blood and can quickly transfer menstrual blood from the top sheet 2 to the absorbent body 4, so that menstrual blood discharged by the wearer is It becomes difficult to spread from the blood modifying agent application region 8B to the outer plane direction. Therefore, the effect of the inner squeezing groove 21B that blocks the spread of menstrual blood in the width direction and efficiently transfers menstrual blood to the absorber 4 can be further enhanced. In addition, the blood modifying agent application region 8B can suppress menstrual blood from reaching the outer pressing groove 22B, so that the top sheet 2, the absorbent body 4 and the back sheet 3 in the outer pressing groove 22B by the penetration of menstrual blood. It becomes possible to suppress the mutual bond between the two and the rigidity of the absorbent article 1B from being lowered.

  In addition, if it has the inner side pressing groove 21B and the outer side pressing groove 22B surrounding the inner side pressing groove 21B, the number of the pressing grooves provided in the top sheet 2 is not limited to two.

(Third embodiment)
A third embodiment of the present invention will be described with reference to the drawings, but the present invention is not limited to what is described in the drawings. In addition, the same code | symbol is attached | subjected to the part which is common in the 1st Embodiment of this invention, and a different part from the 1st Embodiment of this invention is mainly demonstrated.

  FIG. 4 is a plan view of an absorbent article according to a third embodiment of the present invention, and FIG. 5 is a schematic cross-sectional view showing a cross section taken along the line CC of FIG. As shown in FIGS. 4 and 5, in the absorbent article 1 </ b> C of the third embodiment, the bulk of the central portion 61 </ b> C in the longitudinal direction and the width direction is higher than the portions at both ends in the longitudinal direction and the portions at both sides in the width direction. It has become. Therefore, the absorbent article 1C of the third embodiment has a structure in which the bulk of the central portion 61C in the longitudinal direction and the width direction is higher than the portions at both ends in the longitudinal direction and the portions at both sides in the width direction, that is, a medium-high structure. Have In the absorbent article 1C of the third embodiment, only the bulk of the central portion in the longitudinal direction may be higher than the portions at both ends in the longitudinal direction, or only the bulk of the central portion in the width direction. It may be higher than the portions on both sides in the width direction. In the mid-high structure of the absorbent article 1C of the third embodiment, the basis weight of the central part of the absorbent body is made higher than the basis weight of the part around the center of the absorbent body, or around the central part of the absorbent body. It can be formed by embossing or by providing a cushion sheet in the central part of the absorbent body. Thereby, the absorbent article 1C can be brought into contact with the portion from which the menstrual blood of the wearer is discharged. Then, menstrual blood discharged from the wearer can be quickly transferred from the top sheet 2 to the absorbent body 4 without greatly diffusing in the plane direction on the top sheet 2.

  The top sheet 2 has a blood modifying agent application region 8 </ b> C where a blood modifying agent is applied to the portion 61 </ b> C where the bulk of the absorbent article 1 </ b> C is high, that is, the middle / high portion 61 </ b> C. As described above, the blood modifying agent lowers the viscosity and surface tension of menstrual blood and can quickly transfer menstrual blood from the top sheet 2 to the absorbent body 4, so that menstrual blood discharged by the wearer is It becomes difficult to spread from the blood modifying agent application region 8C toward the outside in the planar direction. Therefore, the menstrual blood discharged from the wearer can be quickly transferred from the top sheet 2 to the absorbent body 4 without being diffused greatly in the plane direction by the top sheet 2 due to the medium-high structure of the absorbent article 1C. The above-mentioned effect of being able to be made can be further increased. Further, when the blood modifying agent has a skin care effect, the blood modifying agent application region 8C of the top sheet 2 comes into contact with the wearer's skin due to the medium-high structure of the absorbent article 1C. The skin care effect can be demonstrated greatly.

(Fourth embodiment)
A fourth embodiment of the present invention will be described with reference to the drawings, but the present invention is not limited to what is described in the drawings. In addition, the same code | symbol is attached | subjected to the part which is common in the 1st Embodiment of this invention, and a different part from the 1st Embodiment of this invention is mainly demonstrated.

  FIG. 6 is a plan view of an absorbent article according to a fourth embodiment of the present invention. In the absorbent article 1D of the fourth embodiment, the pair of wing portions 7 are folded inward in the width direction on the skin side. A release sheet 41 is attached to the adhesive portion 12. The top sheet 2 of the absorbent article 1D has a blood modifying agent application region 8D within a range covered with the release sheet 41. Thereby, since it can suppress that the blood modifying material application area | region 8D is exposed by the peeling sheet 41 at the time of manufacture of the absorbent article 1D, it can adhere to the location where a blood modifier does not intend at the time of manufacture of the absorbent article 1D. Can be suppressed.

(Fifth embodiment)
A fifth embodiment of the present invention will be described with reference to the drawings, but the present invention is not limited to what is described in the drawings. In addition, the same code | symbol is attached | subjected to the part which is common in the 1st Embodiment of this invention, and a different part from the 1st Embodiment of this invention is mainly demonstrated.

  FIG. 7 is a plan view of an absorbent article according to a fifth embodiment of the present invention. In the absorbent article 1E of the fifth embodiment, the pair of wing portions 7 are folded inward in the width direction on the skin side. A release sheet 41 is attached to the adhesive portion 12. The top sheet 2 of the absorbent article 1D has a blood modifying agent application region 8E within a range covered with the pair of folded wing portions 7. Thereby, since it can suppress that blood-modifying-material application | coating area | region 8E is exposed by the peeling sheet 41 at the time of manufacture of the absorbent article 1E, it can adhere to the location where a blood modifier does not intend at the time of manufacture of the absorbent article 1E. Can be suppressed.

(Sixth embodiment)
A sixth embodiment of the present invention will be described with reference to the drawings, but the present invention is not limited to what is described in the drawings. In addition, the same code | symbol is attached | subjected to the part which is common in the 1st Embodiment of this invention, and a different part from the 1st Embodiment of this invention is mainly demonstrated.

  FIG. 8 is a plan view of an absorbent article according to a sixth embodiment of the present invention. As shown in FIG. 8, in the absorbent article of 6th Embodiment, the length of the longitudinal direction of the area | region 52 which covers a wearer's buttocks is longer than the length of the longitudinal direction of the area | region 51 which covers a wearer's lower abdomen. long. The absorbent article 1F of the sixth embodiment is an absorbent article worn by the wearer at bedtime, that is, an absorbent article for night use. The top sheet 2 has a blood modifying agent application region 8F, and the blood modifying agent application region 8F is a region of the wearer's buttocks with respect to the region 26 facing the discharge port through which the menstrual blood of the wearer is discharged when worn. Near the region 52 covering As a result, menstrual blood that has flowed through the skin through the wearer's menstrual blood discharge port to the buttocks when the wearer is lying on her back also passes through the blood modifier in the blood modifier application region 8F. The blood viscosity and surface tension can be lowered, and menstrual blood can be quickly transferred from the top sheet 2 to the absorber 4.

  It is also possible to combine one or more of the embodiments.

  The above description is merely an example, and the present invention is not limited to the above embodiment.

  The following examples confirmed that the blood modifying agent can reduce the viscosity and surface tension of menstrual blood and quickly transfer menstrual blood from the top sheet 2 to the absorbent body 4. Hereinafter, although an example is given and the present invention is explained, the present invention is not limited to these examples.

[Example 1]
[Evaluation of rewetting rate and absorber transfer speed]
A commercially available sanitary napkin was prepared. The sanitary napkin includes a top sheet formed from an air-through nonwoven fabric (composite fiber made of polyester and polyethylene terephthalate, basis weight: 35 g / m ² ) treated with a hydrophilic agent, and an air-through nonwoven fabric (composite made of polyester and polyethylene terephthalate). Second sheet formed from fiber, basis weight: 30 g / m ² ), pulp (basis weight: 150 to 450 g / m ² , more in the center), acrylic superabsorbent polymer (basis weight: 15 g / m ² ) And an absorbent body containing a tissue as a core wrap, a side sheet treated with a water repellent, and a back sheet made of a polyethylene film.

The blood modifying agents used in the experiment are listed below.
[Ester of (A ₁ ) chain hydrocarbon tetraol and fatty acid]
Unistar H-408BRS, manufactured by NOF Corporation Tetra-2-ethylhexanoic acid pentaerythritol UNISTAR H-2408BRS-22, manufactured by NOF Corporation Tetra-2-ethylhexanoic acid pentaerythritol and di-2-ethylhexanoic acid neopentyl Mixture with glycol (58:42, weight ratio)

[(A ₂ ) Ester of Chain Hydrocarbon Triol and Fatty Acid]
・ Cetiol SB45DEO, manufactured by Cognis Japan Co., Ltd. Fatty acid is oleic acid or stearyl acid, triester of glycerin and fatty acid ・ Tri-C2L oil fatty acid glyceride, manufactured by NOF Corporation C ₈ fatty acid: C ₁₀ fatty acid: C Triester / tri-CL oil fatty acid glycerides of glycerin and fatty acid containing ₁₂ fatty acids in a weight ratio of approximately 37: 7: 56, manufactured by NOF Corporation C ₈ fatty acids and C ₁₂ fatty acids approximately 44 : Triester of glycerin and fatty acid, contained in a weight ratio of 56

· PANACET 810s, NOF Corp. C ₈ fatty acids: fatty acids to C ₁₀ are contained in approximately 85:15 weight ratio of tri-ester PANACET 800 of glycerin and fatty acids, manufactured by NOF Corporation fatty Triester of glycerin and fatty acid, all octanoic acid (C ₈ )

・ Panasate 800B, manufactured by NOF Corporation All fatty acids are 2-ethylhexanoic acid (C ₈ ), triester of glycerin and fatty acid NA36, manufactured by NOF Corporation C ₁₆ fatty acids: C ₁₈ fatty acids: C Triester of glycerin and fatty acid containing ₂₀ fatty acids (including both saturated and unsaturated fatty acids) in a weight ratio of approximately 5: 92: 3

· Tri-coconut oil fatty acid glyceride, NOF fatty Ltd. C _8: fatty C _10: fatty acid C _12: fatty acid C _14: (including both saturated and unsaturated fatty acids) fatty acids C ₁₆ is approximately 4 : 8: 60: 25: are included in a weight ratio of 3, triesters · SOY42, manufactured by NOF Corporation C ₁₄ fatty acid of glycerin and fatty acids: fatty acids C _16: fatty acid C _18: to C ₂₀ Triester of glycerin and fatty acid containing fatty acids (including both saturated and unsaturated fatty acids) in a weight ratio of approximately 0.2: 11: 88: 0.8

- caprylic acid diglyceride, manufactured by NOF Corporation fatty acid is octanoic acid, diesters of glycerin and fatty acid [(A ₃₎ an ester of a chain hydrocarbon diol and fatty acid]
・ COMPOL BL, NOF Co., Ltd. Butylene glycol dodecanoic acid (C ₁₂ ) monoester ・ COMPOL BS, NOF Corporation Butylene glycol octadecanoic acid (C ₁₈ ) monoester ・ Unistar H-208BRS, NOF Di-2-ethylhexanoic acid neopentyl glycol

[(C ₃ ) Ester of linear hydrocarbon dicarboxylic acid having 2 carboxyl groups, hydroxy acid, alkoxy acid or oxo acid and aliphatic monohydric alcohol]
・ Dioctyl adipate, manufactured by Wako Pure Chemical Industries, Ltd. [Ester of (D ₃ ) fatty acid and aliphatic monohydric alcohol]
Electol WE20, ester of dodecanoic acid (C ₁₂ ) manufactured by NOF Corporation and dodecyl alcohol (C ₁₂ ), Electol WE40, tetradecanoic acid (C ₁₄ ) manufactured by NOF Corporation, and dodecyl alcohol (C ₁₂ ) Esters

[(E ₁₎ poly C _{2 ~ 6} alkylene glycol]
・ Uniol D-1000 (Uniol is all made by NOF Corporation)
Polypropylene glycol uniol D-1200 having a weight average molecular weight of about 1,000
Polypropylene glycol uniol D-3000 having a weight average molecular weight of about 1,200

Polypropylene glycol uniol D-4000 having a weight average molecular weight of about 3000
Polypropylene glycol uniol PB500 with a weight average molecular weight of about 4000
Polybutylene glycol uniol PB700 having a weight average molecular weight of about 500
Polyoxybutylene polyoxypropylene glycol uniol PB1000R having a weight average molecular weight of about 700
Polybutylene glycol with a weight average molecular weight of about 1000

[(E ₂₎ an ester of a poly C _{2 ~ 6} alkylene glycol and fatty acid]
Will Bright cp9, manufactured by NOF Corporation both terminal OH groups are esterified by hexadecanoic acid (C _16), polybutylene glycol having a weight average molecular weight of about 1,100 [(E ₃₎ poly C _{2 ~ 6} Ether of alkylene glycol and fatty acid]
・ Uniluve MS-70K, NOF Co., Ltd. polypropylene glycol stearyl ether, about 15 repeating units

[(F ₁ ) chain alkane]
Pearl Ream 6, manufactured by NOF Corporation Branched chain hydrocarbons produced by copolymerizing liquid isoparaffin, isobutene and n-butene and then adding hydrogen, degree of polymerization: about 5 to about 10

[Others]
・ NA50, made by NOF Corporation Hydrogen added to NA36 to reduce the ratio of double bond derived from unsaturated fatty acid as raw material Triester of glycerin and fatty acid ・ (Caprylic acid / Capric acid) monoglyceride, Japan Monoester of glycerin and fatty acid containing Octanoic acid (C ₈ ) and Decanoic acid (C ₁₀ ), approximately 85:15, manufactured by Oil Co., Ltd. Monomuls 90-L2 lauric acid monoglyceride, Cognis Japan Co., Ltd. Made by company

・ Uniox HC60, polyoxyethylene hydrogenated castor oil manufactured by NOF Corporation

・ Wilbright s753, NOF Corporation polyoxyethylene polyoxypropylene polyoxybutylene glycerin ・ Isopropyl citrate, manufactured by Tokyo Chemical Industry ・ Uniol D-400
Polypropylene glycol uniol TG-330 having a weight average molecular weight of about 400, manufactured by NOF Corporation Glyceryl ether of polypropylene glycol, about 6 repeating units, weight average molecular weight: about 330

-Uniol TG-1000, manufactured by NOF Corporation Polyglycol glycol glyceryl ether, about 16 repeating units, weight average molecular weight: about 1000
Unilube DGP-700, manufactured by NOF Corporation Polyglycol glycol diglyceryl ether, about 9 repeating units, weight average molecular weight: about 700
-PEG 1500, manufactured by NOF Corporation, polyethylene glycol having a weight average molecular weight of about 1,500 to about 1,600

Nonionic S-6, polyoxyethylene monostearate manufactured by NOF Corporation, about 7 repeating units, weight average molecular weight: about 600
・ Vaseline, manufactured by Cognis Japan Co., Ltd. Petroleum-derived hydrocarbon, semi-solid

Table 2 shows the IOB, melting point and water solubility of the sample.
The water solubility was measured according to the method described above, but 20.0 g was added to 100 g of demineralized water, and the sample dissolved after 24 hours was evaluated as “20 g <”, and the sample was dissolved in 100 g of demineralized water. , 0.05 g dissolved but 1.00 g not dissolved sample was evaluated as 0.05-1.00 g.
Regarding the melting point, “<45” means that the melting point is less than 45 ° C.

The skin contact surface of the top sheet of the sanitary napkin was coated with the blood modifying agent described above. Each blood modifying agent is heated as it is if the blood modifying agent is liquid at room temperature, and if the blood modifying agent is solid at room temperature, it is heated to melting point + 20 ° C., and then control seam HMA gun Each blood modifying agent was atomized and applied to the skin contact surface of the top sheet so that the basis weight was approximately 5 g / m ² .

In Example 1, the range in which the top sheet contains a blood modifying agent is shown in FIG. As shown in FIG. 9, in Example 1, almost the entire surface of the top sheet 220 of the sanitary napkin 200 is a blood modifying agent-containing region 240 containing a blood modifying agent. In addition, in FIG. 9, the code | symbol 230 shows a pressing part.
FIG. 10 is an electron micrograph of the skin contact surface of the top sheet in a sanitary napkin (No. 5) in which the top sheet contains tri-C2L oil fatty acid glycerides. As is clear from FIG. 10, the tri-C2L oil fatty acid glyceride is in the form of fine particles and is present on the surface of the fiber.

[Test method]
An acrylic plate with a hole (200 mm × 100 mm, 125 g, a hole of 40 mm × 10 mm is opened in the center) is placed on the top sheet containing each blood modifying agent, and 37 ± 1 ° C. from the hole. 3 g of equine EDTA blood (with equine blood added with ethylenediaminetetraacetic acid (hereinafter referred to as “EDTA”) to prevent coagulation) (1st time) using a pipette 3 g of equine EDTA blood at 37 ± 1 ° C. was dropped again with a pipette from the hole in the acrylic plate (second time).

Immediately after the second drop of blood, remove the acrylic plate immediately, place 10 pieces of filter paper (50 mm x 35 mm) at the place where the blood was dropped, and place a weight on top of it so that the pressure is 30 g / cm ^2. It was. After 1 minute, the filter paper was taken out, and the “rewetting rate” was calculated according to the following formula.
Rewetting rate (%) = 100 × (filter paper mass after test−initial filter paper mass) / 6

In addition to the evaluation of the rewet rate, “absorber transfer rate”, which is the time for blood to transfer from the top sheet to the absorber, was measured after the second drop of blood. The above-mentioned absorption body transfer speed means the time from when blood is introduced into the absorption body until the red color of blood is not seen on the surface and inside of the top sheet.
The results of the rewet rate and the absorber transfer speed are shown in Table 2 below.

Moreover, the whiteness of the skin contact surface of the top sheet after the test of the absorber transition speed was visually evaluated according to the following criteria.
A: Almost no red blood remains, and it is not possible to distinguish between a place where blood is present and a place where blood does not exist. ○: Although a little red blood remains, It is difficult to distinguish the place where it does not exist. Δ: Some red blood remains, and the place where the blood existed. X: Red blood remains as it is. Shown in

  In the absence of a blood modifying agent, the rewetting rate was 22.7% and the absorber transfer rate was more than 60 seconds, but all triesters of glycerin and fatty acids had a rewetting rate. Since it is 7.0% or less and the absorber transfer speed is 8 seconds or less, it can be seen that the absorption performance is greatly improved. However, among the triesters of glycerin and fatty acid, NA50 having a melting point exceeding 45 ° C. did not significantly improve the absorption performance.

  Similarly, a blood modifying agent having an IOB of about 0 to about 0.60, a melting point of about 45 ° C. or less, and a water solubility of about 0.05 g or less with respect to 100 g of water at 25 ° C. greatly improves the absorption performance. I found out that

Next, no. No. 1-42 sanitary napkins were worn by a plurality of volunteer subjects. In the sanitary napkin containing 1 to 28 blood modifying agents, the top sheet was not sticky even after menstrual blood was absorbed, and the answer was that the top sheet was smooth. In particular, these are no. The answer that the difference with the sanitary napkin of 29, 32, 39, 41, and 42 was remarkable was obtained.
No. 1 to 28 sanitary napkins, and in particular No. In the sanitary napkin containing the blood modifying agents 1 to 11, 15 to 18 and 28, the skin contact surface of the top sheet after absorbing menstrual blood is not stained red with blood, and there is little discomfort Got an answer.

[Example 2]
The above rewet rate was evaluated for various blood samples of animals. The blood used in the experiment is as follows.
[Animal species]
(1) Human (2) Horse (3) Sheep

[Blood species]
・ Defibrinated blood: After collecting blood, stirred for about 5 minutes in an Erlenmeyer flask with glass beads ・ EDTA blood: 65 mL of venous blood plus 0.5 mL of 12% EDTA / 2K physiological saline

[Fractionation]
Serum or plasma: supernatant after centrifugation of defibrinated blood or EDTA blood at about 1900 G at room temperature for 10 minutes, respectively. Blood cell: serum is removed from the blood, and the residue is converted to phosphate buffered saline (PBS ) Washed twice and then added with phosphate buffered saline for the removed serum

Absorbent articles were produced in the same manner as in Example 1 except that the tri-C2L oil fatty acid glyceride was applied so that the basis weight was approximately 5 g / m ^2, and the above-described rewetting rates of various blood were evaluated. The measurement was performed 3 times for each blood, and the average value was adopted.
The results are shown in Table 3 below.

  Similar trends to equine EDTA blood obtained in Example 1 were obtained with human and sheep blood. Similar trends were also observed in defibrinated blood and EDTA blood.

[Example 3]
[Evaluation of blood retention]
The blood retention in the top sheet containing the blood modifying agent and the top sheet not containing the blood modifying agent was evaluated.

[Test method]
(1) Tri C2L oil fatty acid glyceride was applied to the skin contact surface of the top sheet formed from an air-through nonwoven fabric (a composite fiber composed of polyester and polyethylene terephthalate, basis weight: 35 g / m ² ) using a control seam HMA gun. It is atomized and applied so that the basis weight is approximately 5 g / m ² . Moreover, the thing which has not apply | coated the tri C2L oil fatty-acid glyceride is also prepared for a comparison. Next, both the top sheet coated with tri C2L oil fatty acid glyceride and the uncoated top sheet are cut to a size of 0.2 g, and the mass (a) of the cell strainer + top sheet is accurately determined. taking measurement.

(2) About 2 mL of horse EDTA blood is added from the skin contact surface side and allowed to stand for 1 minute.
(3) Place cell strainer in centrifuge tube and spin down to remove excess horse EDTA blood.
(4) The weight (b) of the top sheet containing the cell strainer + horse EDTA blood is measured.
(5) The initial absorption amount (g) per 1 g of the top sheet is calculated according to the following formula.
Initial absorption amount = [weight (b) −weight (a)] / 0.2
(6) The cell strainer is reset in the centrifuge tube and centrifuged at about 1200 G for 1 minute at room temperature.

(7) Measure weight (c) of top sheet containing cell strainer + horse EDTA blood.
(8) The post-test absorption amount (g) per 1 g of the top sheet is calculated according to the following formula.
Absorption after test = [weight (c) −weight (a)] / 0.2
(9) Blood retention (%) was calculated according to the following formula.
Blood retention rate (%) = 100 × absorption after test / initial absorption The measurement was performed three times and the average value was adopted.
The results are shown in Table 4 below.

  It is suggested that the top sheet containing the blood modifying agent has low blood retention and can be rapidly transferred to the absorber after absorbing the blood.

[Example 4]
[Viscosity of blood containing blood modifying agents]
The viscosity of blood containing a blood modifying agent was measured using Rheometric Expansion System ARES (Rheometric Scientific, Inc). 2% by mass of panacet 810s was added to equine defibrinated blood, and the sample was gently stirred to form a sample. . Because of the parallel plate, the sample did not have a uniform shear rate, but the average shear rate displayed on the instrument was 10 s ⁻¹ .

The viscosity of equine defibrinated blood containing 2% by mass of panacet 810s was 5.9 mPa · s, while the viscosity of equine defibrinated blood containing no blood modifying agent was 50.4 mPa · s. Therefore, it can be seen that equine defibrinated blood containing 2% by mass of panacet 810s lowers the viscosity by about 90% compared to the case where no blood modifying agent is contained.
Although blood is known to contain components such as blood cells and have thixotropic properties, the blood modifying agent of the present disclosure is considered to be able to lower the viscosity of blood in a low viscosity range. It is considered that the absorbed menstrual blood can be quickly transferred from the top sheet to the absorber by lowering the viscosity of the blood.

The blood modifying agent is prepared by adding 2% by mass of the blood modifying agent to equine defibrinated blood to quickly transfer absorbed menstrual blood from the top sheet to the absorbent body, at 37 ° C. and a shear rate of 10 s. ^{When the} viscosity is measured under the condition of ^-1 , the viscosity of the equine defibrinated blood is preferably reduced by at least 50%, more preferably by at least 60%, and at least 70% lower than before addition. More preferably, and most preferably at least 80% lower.

[Example 5]
[Micrograph of blood containing blood modifying agent]
The menstrual blood of healthy volunteers was collected on saran wrap, and a portion of panacet 810s dispersed in 10 times the mass of phosphate buffered saline was added so that the concentration of panacet 810s was 1% by mass. . Menstrual blood was appropriately applied to a slide glass, covered with a cover glass, and the state of red blood cells was observed with an optical microscope. A photomicrograph of menstrual blood containing no blood modifying agent is shown in FIG. 11 (a), and a photomicrograph of menstrual blood containing panacet 810s is shown in FIG. 11 (b).

  From FIG. 11, in menstrual blood that does not contain a blood modifying agent, red blood cells form a collective lump such as remuneration, but in menstrual blood that includes panacet 810s, red blood cells are each stably dispersed. I understand. Therefore, it is suggested that the blood modifying agent functions to stabilize red blood cells in the blood.

[Example 6]
[Surface tension of blood containing blood modifying agents]
The surface tension of blood containing a blood modifying agent was measured by a pendant drop method using a contact angle meter Drop Master 500 manufactured by Kyowa Interface Science Co., Ltd. The surface tension was measured after adding a predetermined amount of blood modifying agent to sheep defibrinated blood and shaking sufficiently.
Although the measurement is automatically performed by the instrument, the surface tension γ is obtained by the following equation (see FIG. 12).

γ = g × ρ × (de) ² × 1 / H
g: Gravity constant 1 / H: Correction term obtained from ds / de ρ: Density de: Maximum diameter ds: Diameter at a position that is de higher than the dropping end

The density ρ is defined in 5. of “Density Test Method and Density / Mass / Capacity Conversion Table” of JIS K 2249-1995. Based on the vibration density test method, the temperature was measured as shown in Table 5.
For the measurement, DA-505 of Kyoto Electronics Industry Co., Ltd. was used.
The results are shown in Table 5 below.

From Table 5, it is clear from the fact that the blood modifying agent has a water solubility of 0.05 g or less with respect to 100 g of water at 25 ° C., but the solubility in water is very low. You can see that it can be lowered.
By reducing the surface tension of the blood, it is considered that the absorbed blood can be quickly transferred to the absorbent body without being held between the fibers of the top sheet.

1A-1F, 200 Absorbent article 2 Top sheet 3 Back sheet 4 Absorber 5 Side sheet 6 Main body part 7 Wing part 8A-8F Blood modifying agent application area 9, 10 Seal part 11, 12 Adhesive part 21B, 22B, 230 Squeezing groove

Claims (12)

A liquid-permeable top sheet provided on the skin side having a longitudinal direction and a width direction, a liquid-impermeable back sheet provided on the clothing side, and interposed between the top sheet and the back sheet An absorbent article comprising a liquid-retaining absorbent and a pair of side sheets provided on both sides in the width direction of the top sheet,
The top sheet has a blood modifying agent- containing region containing a blood modifying agent,
The blood modifying agent has an IOB of 0 to 0.60, a melting point of 45 ° C. or less, and a water solubility of 0.05 g or less with respect to 100 g of water at 25 ° C., and at least one of the blood modifying agents Part liquefies or is liquid when contacted with body fluid at 40 ° C.,
The blood modifying agent- containing region does not reach the end of the absorbent article,
The blood modifying agent- containing region does not reach the region where the top sheet and the side sheet overlap,
The absorbent article. The top sheet and the back sheet have a seal part joined to the end part by embossing or an adhesive,
The absorbent article according to claim 1, wherein the blood modifying agent- containing region does not reach the seal portion of the absorbent article. The topsheet has an absorber existing area where the absorber is present on the clothing side of the topsheet;
The absorbent article according to claim 1 or 2, wherein the blood modifying agent- containing region is within the range of the absorber existing region. The top sheet includes an annular inner pressing groove that surrounds a region facing a discharge port through which the menstrual blood of the wearer is discharged when worn, and is longer in the longitudinal direction than the width direction, and an outer pressing groove that surrounds the inner pressing groove. Has
The blood modifying agent- containing region is provided inside the outer pressing groove, and is provided in the top sheet so that the inner pressing groove is included in the blood modifying agent region. The absorbent article of any one of Claims. Compared to the longitudinally opposite ends and / or the widthwise opposite sides of the absorbent article, the absorbent article has middle and high portions that are bulky at the center in the longitudinal and / or widthwise direction,
The absorptive article according to any one of claims 1 to 3 in which said top sheet has said blood modifying agent content field in said middle and high part. Having a pair of wings extending in the width direction,
An adhesive part is provided on the clothing side surface of the wing part,
A release sheet is attached to the adhesive portion,
The pair of wing parts are folded inward in the width direction on the skin side,
The absorbent article according to any one of claims 1 to 5, wherein the top sheet has the blood modifying agent- containing region in a range covered with the release sheet. Having a pair of wings extending in the width direction,
The pair of wing parts are folded inward in the width direction on the skin side,
The absorbent article according to any one of claims 1 to 5, wherein the top sheet has the blood modifying agent- containing region within a range covered by the pair of folded wing portions. The absorbent article includes a region that covers the buttocks of the wearer and a region that covers the lower abdomen of the wearer,
The length in the longitudinal direction of the area covering the buttocks of the wearer is longer than the length in the longitudinal direction of the area covering the lower abdomen of the wearer,
The blood modifying agent- containing region is located closer to a region covering the wearer's buttocks with respect to a region facing a discharge port through which the menstrual blood of the wearer is discharged when worn. Absorbent article according to item. The blood modifying agent is
(I) hydrocarbons,
(Ii) a compound in which at least one carbonyl bond (—CO—) and / or at least one ether bond (—O—) is inserted between C—C single bonds of hydrocarbon, or (iii) At least one carbonyl bond (—CO—) and / or at least one ether bond (—O—) is inserted between the C—C single bonds, and at least one hydrogen atom on the hydrocarbon is a carboxyl group ( -COOH) or a compound substituted with a hydroxyl group (-OH),
Here, in the compound of (ii) or (iii), when two or more ether bonds are inserted, the ether bonds are not adjacent to each other.
The absorbent article of any one of Claims 1-8. The blood modifying agent is
(I ′) hydrocarbon,
(Ii ′) at least one carbonyl bond (—CO—), at least one ester bond (—COO—), at least one carbonate bond (—OCOO—) and / or between the C—C single bonds of the hydrocarbon; A compound in which at least one ether bond (—O—) is inserted, or (iii ′) at least one carbonyl bond (—CO—), at least one ester bond (— COO-), at least one carbonate bond (-OCOO-) and / or at least one ether bond (-O-), and at least one hydrogen atom on the hydrocarbon is a carboxyl group (-COOH) or A compound substituted with a hydroxyl group (—OH),
Where, in the compound of (ii ′) or (iii ′), when two or more bonds are inserted, each bond is not adjacent,
The absorptive article according to any one of claims 1 to 9. The blood modifying agent is
(A) an ester of a compound having 2 to 4 hydroxyl groups and a compound having 1 carboxyl group,
(B) an ether of a compound having 2 to 4 hydroxyl groups and a compound having 1 hydroxyl group,
(C) an ester of a compound having 2 to 4 carboxyl groups and a compound having 1 hydroxyl group,
(D) The hydrocarbon has any one selected from the group consisting of an ether bond (—O—), a carbonyl bond (—CO—), an ester bond (—COO—), and a carbonate bond (—OCOO—). Inserted compound,
(E) poly C _2-6 alkylene glycol, or an ester or ether thereof, or (F) a chain hydrocarbon,
The absorbent article according to any one of claims 1 to 10, wherein The blood modifying agent comprises (A ₁ ) an ester of a chain hydrocarbon tetraol and a fatty acid, (A ₂ ) an ester of a chain hydrocarbon triol and a fatty acid, (A ₃ ) a chain hydrocarbon diol and a fatty acid. An ester of (B ₁ ) a chain hydrocarbon tetraol and an aliphatic monohydric alcohol, (B ₂ ) an ether of a chain hydrocarbon triol and an aliphatic monohydric alcohol, (B ₃ ) a chain hydrocarbon An ether of a diol and an aliphatic monohydric alcohol, (C ₁ ) an ester of a linear hydrocarbon tetracarboxylic acid having four carboxyl groups, a hydroxy acid, an alkoxy acid or an oxo acid and an aliphatic monohydric alcohol; C ₂₎ chain hydrocarbon tricarboxylic acids having 3 carboxyl groups, hydroxy acids, esters of alkoxy acids or oxoacids, and aliphatic monohydric alcohols, (C ₃₎ Chain hydrocarbon dicarboxylic acids having number of carboxyl groups, ether hydroxy acid, alkoxy acid or oxo acid, an ester of an aliphatic monohydric alcohol, and (D ₁₎ aliphatic monohydric alcohol and an aliphatic monohydric alcohol , (D ₂₎ dialkyl ketone, (D ₃₎ an ester of a fatty acid and an aliphatic monohydric alcohol, (D ₄₎ dialkyl carbonates, (E ₁₎ poly C _{2 to 6} alkylene glycol, (E ₂₎ poly _{C. 2 to} Esters of ₆ alkylene glycols and fatty acids, (E ₃ ) ethers of poly C _2-6 alkylene glycols and aliphatic monohydric alcohols, (E ₄ ) poly C _2-6 alkylene glycols and chain hydrocarbon tetracarboxylic acids , esters of chain hydrocarbon tricarboxylic acid or chain hydrocarbon dicarboxylic acid, and (E ₅₎ poly C _{2 to 6} alkylene glycol chain Hydrocarbon tetraol, an ether of a chain hydrocarbon triol or chain hydrocarbon diol, and (F ₁₎ is selected from the group consisting of linear alkanes, according to any one of claims 1 to 11 Absorbent article.